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Abstract 
Magnetic particle imaging (MPI) is an emerging imaging modality that specifically 
detects superparamagnetic iron oxide nanoparticles (SPIOs). Our lab has shown that cell 
tracking with magnetic resonance imaging (MRI) has very high sensitivity, but low 
specificity and quantification of iron labeled cells is difficult. MPI cell tracking could 
overcome these limitations. A MomentumTM MPI system was installed at Robarts in 
August 2019 and this is the first project to be completed using MPI. In Chapter 2 a series 
of in vitro experiments are reported which tested the repeatability and reproducibility of 
imaging SPIO labeled cell samples. There are no reports of the use of micron-sized iron 
oxide particles (MPIO) for cell tracking by MPI. Therefore, in Chapter 3, MPIO was 
evaluated for in vivo detection and quantification of cancer cells in the mouse brain by 
MPI. In Chapter 4, limitations of these studies and plans for future work are discussed. 
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Summary for Lay Audience 
 
The purpose of this thesis is to explore a new imaging tool called magnetic particle 
imaging (MPI) to study its ability to detect iron-labeled cancer cells that have been 
dispersed in the brain or cell samples. MPI directly detects iron oxide nanoparticles and 
can be used to provide a measure of the iron content and number of iron labeled cells in 
the brain. Since MPI is so new it is not known what type of iron particle will be ideal for 
cell detection. I explore two different iron particles in this thesis. I labeled breast cancer 
cells that spread to the brain with large micron-sized iron oxide particles and studied how 
well these cells could be detected. I compared this particle with the current gold standard 
for MPI which is called Vivotrax. Experiments were conducted on iron labeled cell samples 
to determine ways to improve image quality, to see if MPI would damage cells during 
scanning, and to compare how imaging and analysis were affected when different users 
conducted scans and analyzed the same data. Iron labeled cancer cells were then injected 
into mice to see how well MPI would be able to detect cells that were dispersed in a mouse 
brain. Images from MPI and MRI were compared to determine the benefits and limitations 
of these complementary imaging tools. Major limitations of the studies and ideas for future 
work are also discussed. 
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Chapter 1  
1 Introduction 
Parts of this introduction have been utilized from a paper I am co-author on titled 
“A Perspective on Cell Tracking with Magnetic Particle Imaging”. (This was published in 
Tomography in November 2020). 
 
1.1 Motivation and Overview 
Magnetic Particle Imaging (MPI) is an emerging imaging modality that directly 
detects superparamagnetic iron oxide nanoparticles (SPIOs).1,2 The Foster lab has been 
developing cellular tracking techniques using Magnetic Resonance Imaging (MRI) for over 
a decade. These cellular tracking techniques have used SPIOs and fluorine-19 (19F)- based 
contrast agents to label cells for multiple applications including immune and stem cell 
tracking for cellular therapies. 3–7 However, these cell tracking techniques using MRI come 
with some limitations. SPIO-based MRI cell tracking has very high sensitivity, but low 
specificity. SPIOs produce negative contrast in MRI, producing signal loss, or signal voids, 
in MRI. This creates an issue as other anatomical features also appear as regions of signal 
loss in MR images. This includes the air in the lungs, cortical bone, and late-stage 
hemorrhage. Therefore, signal void due to iron labeled cells is difficult to differentiate from 
other regions of low signal. Another challenge for MRI cell tracking is the ability to 
accurately quantify the number of cells being detected. The signal loss produced by iron-
labeled cells is indirectly detected through its relaxation effects on protons, making it 
impossible to reliably quantify the local tissue concentration of SPIO.8,9 19F based cell 
tracking uses perfluorocarbons (PFC) to label cells. The number of 19F atoms can be 
directly measured from 19F MR images and related to cell number. 19F MRI has high 
specificity, but low sensitivity; thousands of cells per voxel are needed for detection.10 MPI 
has the potential to overcome challenges related to MRI-based cell tracking because it has 
high specificity (only detects SPIOs) and high sensitivity to nanogram quantities of SPIOs, 
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which translates to hundreds of cells.11 Further improvements in sensitivity are expected, 
especially as tailored SPIOs are developed. Importantly, the MPI signal is linearly related 
to iron mass allowing for quantitation of the amount of iron from images, and with 
knowledge of the amount of iron/cell after SPIO labeling, the cell number can be 
calculated.12  
In August of 2019, Canada’s first MPI system was installed at Robarts Research 
Institute and I was the first student in the Foster lab to have a research project focused on 
the use of MPI for cell tracking. My work focused on using MPI for the detection and 
quantification of breast cancer cells labeled with micron-sized iron oxide particles (MPIO) 
in the mouse brain. This nomenclature for MPIO is accepted and commonly used in the 
cell tracking field. 
 
1.2 Imaging Modalities for In Vivo Cell Tracking 
A number of imaging modalities have been used for imaging cells in preclinical models. 
The most common are bioluminescence imaging (BLI), positron emission tomography 
(PET) and magnetic resonance imaging (MRI). Magnetic particle imaging (MPI) is just 
emerging as an in vivo cell tracking modality. BLI is a low-cost modality with high 
through-put. The most valuable feature of BLI for cell tracking is the ability to differentiate 
between dead and viable cell populations. For BLI, cells are engineered to express a 
luciferase transgene, this is often done using Firefly luciferase (FLuc) or Renilla luciferase 
(RLuc), which reacts with a correlating substrate (D-luciferin for Firefly luciferase or h-
coelenterazine for Renilla luciferase). The reaction produces light as a product of enzyme-
based oxidation of the substrate and photons are collected by a highly sensitive cooled 
charge coupled device (CCD) camera that converts photons into electrons.13 This signal is 
usually overlaid on top of an x-ray or a computed tomography (CT) image for anatomical 
reference. However, BLI has its limitations. BLI is limited by low resolution and the 
inability to image larger animals and humans because of poor tissue penetration of optical 
signals resulting in limited depth penetration.14 PET imaging has the advantage of very 
high sensitivity and unlimited depth penetration. PET provides functional images through 
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the detection of gamma rays that are emitted from radioisotopes. These isotopes are of 
varying half-lives and energies and have been widely used for targeted imaging. However, 
PET images have high background activity and are of relatively low resolution.15 PET 
images are also usually paired with MRI or CT images for anatomical information. The 
use of isotopes for PET exposes the subjects to ionizing radiation. This can be concerning 
for imaging cells, especially in the context of cell therapies. In comparison to other cell 
imaging techniques, MRI has the advantage of high resolution and high tissue contrast. 
MRI is considered safe and uses no ionizing radiation. This allows for serial imaging. 
Cellular MRI relies on contrast agents which present some limitations. Proliferation of cells 
leads to diminished signal and signal can remain visible from cells even after death.8 MRI 
has been developed for cell tracking in the Foster lab and is described in more detail below. 
A schematic showing the relative sensitivity and resolution for these preclinical imaging 
systems used for cell tracking is shown in Figure 1.1. 
 
Figure 1.1: Schematic showing a comparison of resolution and sensitivity of the common imaging modalities used for 
cell tracking. 
 
1.3 MRI Cell Tracking 
Cell tracking with MRI uses contrast agents for labeling specific cells, thereby 
enhancing their detectability.16,17 The most commonly used agents for cell tracking with 
MRI are magnetite (Fe3O4)-based superparamagnetic iron oxide nanoparticles (SPIOs). 
MRI cell tracking was first demonstrated by Bulte et al.18 and Yeh et al.19 in the early 1990s 
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by internalizing iron oxide particles within cells and detecting the resulting negative signal 
contrast. The presence of SPIOs in cells causes a distortion in the magnetic field and leads 
to abnormal signal hypo-intensities in iron-sensitive images (T2- and T2*-weighted images 
are most often used).20 The resulting signal void occupies a much larger spatial region than 
the actual size of the individual cells; this is commonly referred to as a blooming effect. 
This has led to high detection sensitivity, with single cell detection possible under certain 
conditions.21,22  
 The SPIOs used for MRI are usually classified by hydrodynamic size: 1) ultra-small 
superparamagnetic iron oxide nanoparticles (USPIO) (5-50 nm), 2) superparamagnetic iron 
oxide nanoparticles (SPIO) (50-150 nm), and 3) micron-sized iron oxide particles (MPIO) 
(0.5 – 2 μm). Worth noting here is that it is the iron core size, not the hydrodynamic size, 
that is most important in MPI, this is described in detail below. Of the SPIO used for MRI 
cell tracking, MPIO have the highest iron content per particle, as they have approximately 
1pg Fe/particle. This makes one MPIO particle roughly equivalent to 1.5 million standard 
SPIO or 4 million USPIO.23  Although there are no FDA approved SPIO for MRI, one 
agent is currently approved off-label for MRI cell tracking. This is Ferumoxytol, which is 
a USPIO used to treat iron-deficiency.24 As will be described later, many MPI cell tracking 
studies have used the same SPIO that have been used for MRI. 
 There are two strategies for labeling cells with SPIO. Cells can be labeled in vitro 
during cell culture by incubation with the SPIOs, typically overnight. Uptake of SPIOs by 
cells occurs through endocytosis.20 Once internalized SPIOs are compartmentalized in 
endosomes in the cell cytoplasm. This strategy is used when cells are subsequently injected 
or implanted and then imaged.25  Some cells require other methods for efficient uptake. 
Transfection agents can be used to enhance uptake of SPIOs into cells. Transfection agents 
work by coating the outer surface of SPIOs to improve the rate of iron uptake as well as 
the amount of iron taken up by cells. Our lab commonly uses protamine sulfate in 
conjunction with heparin (both FDA approved) to improve cell labeling.26 Alternatively, 
SPIO can be administered intravenously (IV) and phagocytic cells of the 
reticuloendothelial system (macrophages) take up SPIOs in situ.27 This is typically used 
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for imaging macrophages and inflammation. For the work in this thesis cells were labeled 
in vitro with MPIO. 
Labeling efficiency can be tested a few different ways. Staining for iron with Perl’s 
Prussian blue (PPB) can be used to identify iron positive cells. With this method, 
intracellular iron appears blue and the cells are counterstained with nuclear fast red and 
appear red. The labeling efficiency can be then be determined by analysis of cells on slides 
by microscopy and calculating the percentage of blue cells. The mass of iron per cell can 
be measured using inductively coupled plasma mass spectroscopy (ICP-MS) or 
spectrophotometric techniques, these report an average value for the amount of iron per 
cell; some cells will contain more, or less, iron. 
It is important to assess the impact of SPIO on cell phenotype and function. 
Viability can be easily assessed using trypan blue exclusion assay. This assay works off 
the principal that live cells with intact membranes will not take up the blue dye while dead 
cells will because of their compromised membrane integrity.28 Relatively low toxicity has 
been reported in the literature for SPIO labeling of cells in general.29–31 The Foster lab have 
previously shown that most cells can be efficiently labeled with iron with no negative 
impact on viability, migration, maturation or differentiation, when using a variety of 
SPIOs.32,33  Roach et al. showed that hepatocytes could endocytose MPIO, achieving iron 
content as high as ~55 pg/cell, with >75% viability, and extensive morphological and 
functional assays indicated that labeling was benign to the cells.  Some cells are more 
sensitive to labeling with iron than others.34 Rohani et al. demonstrated differences in 
activation and migration of dendritic cells labeled with MPIO.35 Using flow cytometry they 
were able to determine the optimal amount of MPIO for labeling to minimize cell apoptosis 
and maximize detectability by MRI. When testing a new cell and SPIO combination it is 
important to carefully calibrate the ideal iron loading which produces sufficient 
intracellular iron for detection, without adversely affecting cells. For MPI cells are labeled 
the same way and analysis methods are also the same.  
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1.4 Tracking MPIO-Labeled Cancer Cells in the Mouse 
Brain by MRI 
Our lab has used MPIO extensively to label human breast cancer cells (MDA-231-
BR) for tracking by MRI in the mouse brain.36–38 In this animal model MDA-231-BR cells 
are labeled with MPIO particles by co incubation for 24 hours – labeling with MPIO results 
in approx. 20 pg of iron/cell, determined by ICP-MS. Then they are injected into the left 
ventricle of the mouse heart with ultrasound guidance. Approximately 15-20% of cells 
have been shown to arrest in the brain vasculature after intra-cardiac administration. This 
model is used in Chapter 3 were MPI is used to detect MPIO-labeled cells arrested in the 
mouse brain on the day of the injection. 
A number of publications have resulted from studies which used this model in the 
Foster lab. For example, in 2006, Heyn et al. demonstrated that MPIO labeled MDA-231-
BR cells could be detected in the mouse brain at the single cell level.39 In a subsequent 
paper, the ability to monitor non-proliferating, iron-retaining cancer cells was 
demonstrated.21  Later, Murrell et al. used MRI to image MPIO labeled breast cancer cells 
in mice treated with whole brain radiotherapy (WBRT). Early, prophylactic WBRT 
eliminated tumour growth and MRI showed that non-proliferative, MPIO-retaining cancer 
cells were unresponsive to WBRT and persisted in the brain for up to 100 days.40  At this 
time there are no published reports of the use of MPI to detect MPIO labeled cells in vivo.  
 
1.5 Limitations of MRI Cell Tracking with SPIOs 
As described briefly before, there are several limitations of MRI cell tracking with 
SPIO to be aware of. The first is low specificity due to other low-signal regions in images, 
i.e., SPIO-labeled cells in the lung or in a region of hemorrhage cannot be detected as these 
regions appear black like a signal void would. Ultra-short echo time imaging methods 
developed for producing positive contrast from iron-labeled cells have similar problems 
with specificity.41 Second, quantification of iron-induced signal loss is complicated. Our 
group as well as others have shown that signal loss produced by SPIO-labeled cells is only 
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linear at low iron concentrations.42 Typically, the degree of contrast (how black the void 
is) or the volume of signal loss (how big a void is) is measured from these images. Although 
some studies have used MR-based relaxometry to show a linear relationship between 
R2*values and SPIO-labeled cell concentration in samples 43 the in vivo cell quantification 
by this method is more complicated.  Overall, with iron-based MRI cell tracking there are 
issues with specificity and cell number cannot be accurately determined when quantified. 
For these reasons we pursued MPI in this thesis as a quantitative in vivo imaging method 
for cancer cell tracking. 
 
1.6 Cell Tracking with Magnetic Particle Imaging 
MPI is a new imaging modality which directly detects SPIOs. MPI cell tracking has 
the potential to address the limitations presented by SPIO-based cell tracking. First, the 
MPI signal is only generated from SPIOs. This results in positive “hot-spot” contrast, 
similar to PET. There is also no signal attenuated from biological tissues meaning there is 
no background signal that may affect the specificity of MPI. Second, the MPI signal is 
linearly quantitative with iron concentration, and therefore the amount of iron in a region 
of interest can be measured from MPI images and, with information on the amount of 
iron/cell, the number of SPIO labeled cells can be calculated. In addition, MPI uses no 
ionizing radiation which is important for repeat, longitudinal imaging of cells, especially 
in the therapeutic cell setting. 
 
1.7 The MPI System 
MPI was first presented as a novel imaging modality by Weizenecker and Gleich 
in 2005.44,45 The MomentumTM MPI system we use at Robarts Research Institute 
(Magnetic Insight Inc, Almeida, California, USA) works by exploiting the nonlinear 
magnetization of the SPIOs by using weak magnets (mT) and strong gradient fields (T). 
The MPI system has three main components. The magnets, the transmit and receive coils 
and the control console. MPI is built around a gradient magnet system. Two opposing 
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electromagnets form a selection field, which is a strong gradient magnetic field (~ 6 T/m) 
that contains a field free region (FFR) near the isocenter where the magnetic field passes 
through zero (Figure 1.2). The selection field magnetically saturates the magnetization of 
all SPIOs except for those SPIOs in the FFR, which experience no magnetic field. The FFR 
is rapidly rastered over the imaging volume by changing the current through 
electromagnets. When the FFR traverses a location containing SPIOs, the SPIO's 
magnetization changes nonlinearly, producing a magnetization curve characteristic of the 
SPIO used. This change induces a voltage in a receiver coil, and the detected voltage can 
be assigned to the instantaneous FFR location to produce an image, providing spatial 
localization.46 The voltages induced are linearly proportional to the number of SPIOs at the 
FFR location over a wide range of concentrations, enabling quantification of SPIOs. 
 
 
  
Figure 1.2: Two opposing electromagnets form a selection field, which is a strong gradient magnetic field (~ 6 T/m). A 
field free region (FFR) is created near the isocenter where the magnetic field passes through zero. 
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MPI can produce both 2D and 3D images. 2D projection images are acquired by 
shifting the FFR along the y-axis by translating the sample bed. The FFR is shifted along 
the x-axis by changing the electric field strength. These scans are acquired in a grid 
formation from left to right and top to bottom to create a 2D image. The direction of the 
projection can also be chosen (coronal- 0 degrees, or sagittal- 90 degrees). Projection 
images give the sum of the signal along the direction chosen and the signal is resolved in 
the two orthogonal direction to the projection (x, y plane). The acquisition time for 2D 
images ranges between 1-5 minutes depending on the scan mode (described in Chapter 2). 
3D tomographic images are acquired by projection reconstruction similar or x-ray or CT. 
The number of equi-spaced projections and angle can be chosen by the MPI user starting 
as low as 28 projections and as high as 75 projections and angles between 0-360 degrees. 
Increasing the number of projections increases the scan time as well as increase the signal 
to noise ratio (SNR). Our system typically uses 35 projections when acquiring a 3D scan. 
Filtered back projections are used to create a full 3D tomographic image. The signal is 
resolved along all 3 orthogonal directions (x, y, z plane). The entire gantry containing the 
2 electromagnets can be rotated around the sample bed as the sample bed is being translated 
in and out of the bore for the FFR to translate across. These scans are slower taking 
anywhere from 15-30 minutes. 3D images are typically used when acquiring in vivo data 
for accurate localization of signal as well as providing better sensitivity and resolution. The 
scan modes on the MomentumTM MPI system are described in Chapter 2. 
 
1.8 MPI Resolution and Sensitivity 
The resolution of MPI is driven primarily by the gradient strength and the SPIO 
properties (core size and relaxation). There are no voxels in MPI like in MRI, instead 
resolution is related to the size of the FFR. If you increase gradient strength in MPI you 
reduce the size of the FFR, this leads to higher resolution but lower sensitivity since there 
is less iron, and no signal, contained in a single FFR position. Similarly, a decrease in 
gradient strength leads to a larger FFR, lower resolution but higher sensitivity (Figure 1.3).  
The relationships between gradient strength and resolution is illustrated in Figure 1.4 for 
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three core sizes. Theoretical modeling based upon the Langevin theory of SPIOs predicts 
that resolution improves with increasing core size. However, Tay et al. found that improved 
resolution with increasing magnetic core size follows the prediction up to approximately 
25 nm when the effects of SPIO rotational times become significant due to relaxation 
effects (Figure 1.5).47 For this reason, SPIO with a core size close to 25 nm are currently 
considered to be ideal for MPI.  
 
Figure 1.3: Schematic showing how the gradient strength can impact the resolution of MPI by changing the size of the 
FFR. (A) The gradient strength is strong at 6 T/m making the FFR small. (B) The gradient strength is weak at 3 T/m 
where the FFR is much larger. 
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Figure 1.4: The relationship between gradient strength and resolution is shown for four different core sizes. 
 
Figure 1.5: A comparison of the experimentally achieved spatial resolution with the predicted spatial resolution from 
the Langevin model reproduced from reference 33 shows an increasing disparity with increasing core size after 24.4 nm. 
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The relationship between core size and resolution is a little more complicated. The 
core size determines the type of MPI relaxation that occurs in MPI when SPIOs are 
magnetized. MPI SPIO relaxation is much different from MRI proton relaxation. 
Relaxation impacts MPI images because it prevents the SPIO magnetization from 
instantaneously rotating. Another way to think about it is that relaxation acts against the 
SPIOs alignment with the applied field, causing a delay in the magnetization response. 
There are two types on MPI relaxation, Neel and Brownian.  Neel relaxation refers to the 
reversal of the SPIO magnetic moment whereas Brownian relaxation refers to the physical 
rotation of the SPIO, in response to the MPI excitation magnetic field. The dominant 
relaxation mechanism depends on the SPIO core size and also the configuration, spacing 
and orientation of individual cores that make up the effective core size (Figure 1.6). 
Importantly, the study by Tay et al. described above looked at SPIOs which were single 
core particles and most SPIO used in MPI are multi-core clusters (described in more detail 
below).48 The transition from Neel to Brownian occurs at about 15 nm. In simple terms, 
resolution worsens with increasing Brownian relaxation because larger SPIOs experience 
increased viscous drag. The spatial resolution of MPI using currently available commercial 
SPIOs is approximately 1 mm 12 and custom made SPIOs, tailored for MPI have 
demonstrated a resolution of 200 µm.49 Relaxation effects are one of the primary limits to 
resolution in MPI, as SPIO synthesis for MPI evolves, improvements in resolution are 
expected. 
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Figure 1.6: Schematic illustrating the concepts of a single core iron particle, a multi-core particle and the effective core 
size (dc) and the hydrodynamic diameter of SPIOs. 
 
The sensitivity of MPI also depends on both nanoparticle and scanner specific 
factors.  Nanoparticle factors include the strength of the SPIO magnetization and the rate 
of SPIO relaxation at the FFR. Stronger SPIO magnetization improves MPI signal and a 
faster change in magnetization leads to higher MPI signal (Figure 1.7). Cellular sensitivity 
also depends on the efficiency of the nanoparticle cell labeling (more iron per cell leads to 
higher sensitivity).  
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Figure 1.7: Schematic showing the magnetization SPIOs experience within the MPI system. (A) and (B) are comparing 
strength of nanoparticle relaxation. The magnetization curve models the relaxation behaviour of the nanoparticles in 
response to the magnetic field. In (A), a stronger relaxation leads to a taller M-H curve (black), which leads to a higher 
peak intensity (blue). In (B), we see that the M-H curve is not as tall (black) - that means the magnetization of the particle 
is not as strong, and we get a shorter peak (in blue). (C) and (D) are comparing nanoparticle relaxation rate. This is 
looking at the steepness of the magnetization curve. In (C), the M-H curve (black) is almost vertical across the origin. 
This leads to a higher peak (blue) in the point spread function (higher sensitivity). In (D), the M-H curve is not as steep, 
meaning the particle is taking longer to rotate, leading to a shorter peak (blue) in the point spread function (lower 
sensitivity). 
 
Scanner specific factors affecting sensitivity include changing (i) the selection field 
gradient strength, (ii) the amplitude of the excitation field,50 and (iii) averaging. When 
changing these factors there are trade-offs between sensitivity and resolution. As described 
above a decrease in the selection field gradient strength leads to a larger FFR and this leads 
to higher sensitivity because there is more iron, and so signal, contained in the FFR.  The 
excitation field is the strength of the rapidly oscillating RF field that rapidly moves the FFR 
across SPIOs to induce a signal in a receiver coil. A higher excitation field amplitude 
excites the SPIOs more rapidly, allowing for a faster change in magnetization, thereby 
inducing a larger voltage in the receiver coil. Therefore, a higher excitation field amplitude 
gives more signal and higher sensitivity. There is a resolution trade-off where resolution 
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decreases at higher excitation fields because the nanoparticles, due to their relaxation 
properties, and are unable to respond to the applied field fast enough and smear out the 
received signal in the spatial domain. On the MomentumTM MPI system the projection 
images are acquired as 2D panels which are then stitched together to form the entire image. 
The overlap fraction is how much these panels overlap each other and are best thought of 
as a method of averaging.  In this case a higher overlap fraction results in more signal 
averages and more signal for higher sensitivity; the trade-off is scan time. The relationship 
between signal averaging, via overlap fraction, and sensitivity is still under study. 
The in vitro detection limit has been estimated at 200 cells labeled with Vivotrax, 
however, this was based on the detection of 1000 cells in a 100 μL in vitro cell suspension 
with SNR ~5.51  Song et al. reported that as few as 250 cells, labeled with a custom-made 
MPI tailored SPIO (30 pg Fe/cell), could be detected in vivo if a background subtraction 
method was used.52 There is still considerable work to be done to demonstrate and evaluate 
MPI cellular detection limits more closely. 
 
1.9 Nanoparticles for MPI Cell Tracking 
As described above, both MPI sensitivity and resolution are closely related to the 
type of SPIOs.  Many of the SPIOs currently used for MPI are similar to those used for 
MRI cell tracking.  Table 1.1 lists some of the SPIOs that have been tested for MPI.  The 
first SPIO that was shown to be useful for MPI was Resovist, which was previously widely 
used for liver imaging with MRI. Magnetic Insight Inc., the manufacturer of our 
MomentumTM MPI system now sells Resovist manufactured as Vivotrax. Vivotrax is 
currently considered the gold standard for MPI and new SPIO are compared against it, 
since most published studies of MPI have been conducted with this SPIO.51,53–55 Although 
widely used, it is not considered optimal for MPI. This is because Vivotrax is a 
polydisperse mixture of particles containing both single iron cores (~5 nm, 70%) and 
clusters of multiple cores (~25 nm, 30%), leading to a bimodal size distribution.48  The 
single cores are too small to magnetize significantly and so the MPI signal predominately 
originates from the clustered 25 nm multi-core structures (Figure 1.8).  
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Table 1.1: Characteristics of the SPIOs used for MRI and MPI cell tracking. 
 
 
 
Figure 1.8: Schematic for Vivotrax. (A) Vivotrax contains both single core particles (~ 5 nm) and multicore clustered 
particles (~25 nm). (B) The size distribution is bimodal; ~ 70% of the cores are single cores and the other 30% is 
composed of the multicore particles. 
 
Approaches to improve MPI sensitivity include increasing the fraction of these 
larger aggregates56 or by fractionation of Vivotrax.57  The synthesis of homogeneously 
distributed single-core SPIOs with optimized core diameters is also being investigated.58 
Unni et al. have shown that single core particles with uniform physical and magnetic size 
distributions can be synthesized by introducing molecular oxygen in the thermal 
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decomposition synthesis. These SPIOs have improved MPI sensitivity and resolution 
compare to commercially available SPIOs.59  
Ziemian et al. have presented a large-scale water-based synthesis of multicore 
SPIOs stabilized with dextran which they call MC-SPIOs. They also synthesized single 
core SPIOs in organic media, coated with a poly(ethylene glycol) gallic acid polymer and 
phase transferred to water (SC-SPIOs). This group showed that the MC- SPIOs and the SC 
SPIOs had 2.3 and 5.8 fold higher sensitivity than Vivotrax.60 
 
1.10  Characterizing SPIOs for MPI 
A common first step for characterizing SPIOs for MPI is by using MPI relaxometry. 
MPI relaxometry measures the net magnetization of SPIOs, by turning off the selection 
field and applying a negative magnetic field then a positive field, and back. SPIOs in a 
sample are driven from a negative magnetic saturation to positive, and vice versa. The 
output is the derivative of the Langevin function, also called the point spread function 
(PSF). The signal intensity, or height, of the PSF reflects the sensitivity of the SPIO. The 
full-width half maximum (FWHM) relates to the spatial resolution of the SPIO.61 A 
narrower tracer response shown by the FWHM, indicates superior spatial resolution and a 
greater signal intensity per mass of iron indicates superior sensitivity.  
 
1.11  Quantification of MPI Signal 
Quantification of the mass of iron from MPI images is one of the main advantages 
of this modality for cell tracking. The first step for quantifying iron is to measure the MPI 
signal from the image. MPI images should be displayed in full-dynamic range to ensure all 
of the signal is included when choosing the region of interest (ROI). The ROI is traced 
manually by referencing a colour look-up table (CLUT) customized for MPI images in 
Horos using a maximum intensity projection (MIP) for 2D images or slice by slice for 3D 
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images. The output provides mean signal and ROI volume. The MPI signal for the ROI is 
calculated by using the following equation: 
MPI signal = Mean signal in ROI (A. U.) ∗ ROI volume (mm3 or mm2) 
To convert MPI signal to iron content requires a calibration. A calibration line can 
be constructed by measuring the MPI signal from a series of diluted samples of known iron 
content. This is explained in more detail in Chapter 2. Other groups have calibrated the 
MPI signal using a single reference tube with a known iron content for calibration placed 
in the field of view and imaged along with the sample or animal being imaged. A 
disadvantage to this method is that the amount of iron in the reference sample needs to be 
close to the amount of iron expected in the experimental sample. For in vivo experiments 
this may be unknown.  
For a sample prepared with a known number of cells, the average iron content per 
cell can be measured using ICP-MS.  These measurements must be acquired using the same 
cells used for in your imaging experiment. Subsequently, an estimation of cell number from 
in vivo MPI images can be calculated: 
Number of cells in vivo 
= 𝐢𝐫𝐨𝐧	𝐦𝐚𝐬𝐬	𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝	𝐛𝐲	𝐌𝐏𝐈	𝐟𝐫𝐨𝐦	𝐑𝐎𝐈	(𝛍𝐠)
	𝐢𝐫𝐨𝐧	𝐦𝐚𝐬𝐬	𝐩𝐞𝐫	𝐜𝐞𝐥𝐥	𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝	𝐛𝐲	𝐌𝐏𝐈	𝐨𝐫	𝐈𝐂𝐏<𝐌𝐒	𝐟𝐫𝐨𝐦	𝐜𝐞𝐥𝐥	𝐬𝐚𝐦𝐩𝐥𝐞	(𝛍𝐠/𝐜𝐞𝐥𝐥)
  
 
1.12  Cell Tracking with MPI 
Mentioned below are some of the early MPI cell tracking papers. Most papers have 
been of the proof-of-principle nature, demonstrating detection of cells in various models, 
but few have quantified iron content or cell number. So far MPI has been used to image 
stem cells, pancreatic islets, neural progenitor cells (NPCs), breast cancer cells, T cells, 
and tumour-associated macrophages (TAMs). 
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The majority for the cell tracking papers have studied stem cells. The first MPI cell 
tracking paper published was on human embryonic stem cells (hESC) that were labeled 
with Resovist by Saritas et al. Resovist, rebranded as Vivotrax is currently the gold 
standard SPIO for MPI cell tracking. They subcutaneously injected labeled cells into a 
postmortem mouse at two different injection sites. 1.0 x 105 cells were injected on the back 
of the neck and 2.0 x 105 cells on the right hind limb. The mouse was then imaged using 
MPI where images showed no depth attenuation, and no background signal from mouse 
tissue. This demonstrated for the first time that MPI had the potential to detect iron labeled 
cells as high contrast regions in mice.  They quantified the MPI signal and found that the 
ratio between signal intensities was 2 to 1; the injection site containing 2.0 x 105 cells 
showed twice the signal than the 1.0 x 105 cell injection.12  
Zheng et al. for the first time used MPI to longitudinally monitor and quantify the 
biodistribution and clearance of stem cells in vivo. Human mesenchymal stem cells 
(hMSCs) were labeled with Resovist and injected in cell numbers ranging from 5 × 106 to 
8 × 106 into the mouse tail vein. MPI whole body images of the mice were taken over the 
course of 12 days. In the first hour of imaging this group saw that MPI signal accumulated 
in the lungs of mice. As they continued to image out until 12 days, they saw that signal in 
the lungs decreased and relocated to the liver as early as 24 hours post injection. To validate 
the biodistribution of Resovist in mice, the mice were sacrificed, and organs were excised 
and imaged using MPI. Ex vivo MPI of the organs confirmed that signal was accumulating 
in the lungs, liver and to a lesser degree in the spleen. This study was the first to show the 
biodistribution and clearance of Resovist labeled cells using MPI.54   
Bulte et al. have shown that neural and mesenchymal stem cells (MSCs) can be tracked 
with MPI using three different SPIOs Feridex, Resovist and UW particles. Feridex and 
Resovist are both commonly used for MRI cell tracking and have also been used in clinical 
trials. However, these two iron oxide particles are no longer commercially available. This 
led to the motivation to develop and experiment with UW particles which are a MPI 
specific tailored SPIO synthesized by this group. They were able to detect as few as 5.0 
x104  UW labeled stem cells in vivo using MPI when cells were injected into the midline 
 
 
 
20 
 
of the skull. When compared to MRI scans of the same mice the MPI data was in good 
agreement with the location of the regions of hypo-intensity in the MR images.53   
NPCs have been imaged by Zheng et al. 5.0 x 105 NPCs were labeled with Resovist 
and stereotactically implanted into the forebrain of two immunosuppressed rats. To study 
the migration and clearance of these cells they implanted an equivalent number of labeled 
NPCs near the lateral ventricle in a third animal. A fourth rat acted as a control, no cells 
were injected, instead free  Resovist was injected into the forebrain. MPI scans of the brain 
were acquired over time and signal was detected in the brain up until day 87. MPI images 
showed high contrast and no background signal from animal anatomy. MPI images were 
quantified using a calibration curve to quantify iron content. Total MPI signal from the cell 
graft in the first 2 rats had non-significant decay over time. Rat 3 showed the presence of 
iron posterior to the implant site and significant signal clearance compared to the first 2 
rats, indicating the movement and clearance of NPCs were through the ventricular system. 
The control animal receiving free Resovist showed no MPI signal in all the scans.51  
Nejadnik et al. were the first to demonstrate that Ferumoxytol, a USPIO used 
clinically for anemia and approved off-label for MRI cell tracking, can be used to track 
cells by MPI. In this study MSCs were labeled with either Vivotrax or Ferumoxytol and 
implanted into the parietal skull bone of mice and MPI images were compared with MRI. 
MPI showed that the iron content significantly declined over time, which correlated to the 
loss of cells at the implant site which was confirmed by histology. MRI showed no 
significant change in the region of signal loss over the same time.62  
Sehl et al. used MPI and MRI to monitor the fate of Ferumoxytol labeled MSCs 
along with 19F MRI after IV PFC administration to simultaneously image the inflammatory 
response against the transplanted MSCs. This group used calibration lines to quantify iron 
content from MPI images. A decrease in MPI signal over a 12 day period was observed. 
This work is exciting as it is the first time these modalities have been compared. It shows 
promise for therapeutic monitoring as this multimodality imaging approach allows for the 
visualization of MSC delivery to target, and the ability to quantify inflammation and 
measure the amount of MSCs at a specific location.63 
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MPI has also been used to image other therapeutic cell types. For example, Wang 
et al. demonstrated that MPI can be used for the quantitative detection of Vivotrax labeled 
baboon pancreatic islets after transplantation into the liver or under the kidney 
capsule. Mice were imaged on day 1 using MRI to confirm labeled cells were transplanted 
successfully before being imaged postmortem on day 1 or day 14 using MPI.  The MPI 
signal in the kidney decreased between days 1 and 14.  This likely corresponds with a 
decrease in the islet mass, which is normally observed during the first two weeks due to 
graft deterioration. In the same mice they also observed an increase in MPI signal in the 
liver, thought to be due to the accumulation of dead islets in the kidney releasing iron which 
is cleared by the liver. Iron content in the liver and kidney was calculated using a calibration 
curve, similar to the methods used in this thesis. The number of labeled islets could not be 
estimated because the islets for phantom and islets for mice came from different batches 
and were of different quality. They concluded that MPI would be a suitable method for 
imaging these transplanted islet grafts as there is no depth attenuation and zero background 
tissue signal.55  
Song et al. synthesized Janus iron oxide particles for MPI cell tracking. These Janus 
particles showed 3 times the MPI signal intensity of Vivotrax and 7 times of Ferumoxytol. 
Janus particles were used to label human cervical cancer HeLa cells where 30 000 cells 
were subcutaneously injected into the abdomen area and 2500 cells were subcutaneously 
implanted on the back of mice. MPI images were able to detect signal in the abdomen with 
high contrast. The SNR was 16.1. With the 2 500 labeled cells, MPI signal was decreased 
but and the SNR was 1.3. When 250 cells were implanted into the back MPI signal was 
able to be visualized after using background subtraction.  
 Arami et al. synthesized nanoparticles that targeted cancer cells. Mice were injected 
subcutaneously with C6 rat glioma cells into the right flank. Tumours had 3-4 weeks to 
form before mice were injected with the new nanoparticle via the tail vein. They compared 
the targeting results of the nanoparticle by attaching external magnets to the tumours of 
mice. Control mice had no magnet attached to their tumor. 1-2 hours after injection mice 
were imaged using IVIS fluorescent imaging system to evaluate the nanoparticles uptake 
in tumours and in the liver and spleen. Mice were imaged with MPI ex vivo. Reference 
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tubes were used for co registration purposes. MPI images with the lactoferrin conjugated 
nanoparticles were internalized and retained in mouse tumours, and was enhanced when 
there was a magnet attached to mice. MPI results of the excised tumors showed that the 
tumor uptake was best with the combination of magnetic and lactoferrin-assisted targeting 
showing the greatest uptake.64 
MPI has also been used to detect cells labeled in situ by IV administration of SPIOs. 
Makela et al. saw that TAMs labeled with either Ferumoxytol or Vivotrax could be 
visualized by MRI. However, strong MPI signal in the liver due to uptake of SPIOs by 
resident liver macrophages limited the visibility of iron in tumors ex vivo. MPI did detect 
SPIO-positive TAMs in lung metastases which could not be detected by MRI since the 
lungs also appeared with low signal intensity in MR images. This group used calibration 
lines to quantify the amount of iron in MPI images.65  
 Yu et al. also detected breast cancer cells labeled in situ by IV administration using 
an SPIO tailored for MPI called LodeSpin. Rats were injected subcutaneously with 7 
million MDA-MB-231-luc cells allowing for BLI to confirm formation of tumours before 
being injected IV with LodeSpin. Rats were split into Groups A, B, and C. Group A rats 
had tumours in the left lower mammary fat pad and were injected with LodeSpin. Group 
B had tumors at the right lower flank and injected with LodeSpin. Group C was the control 
rat that had no tumour and was just injected with LodeSpin. MPI scans were acquired at 
multiple time points up until day 6. Images showed that SPIOs accumulated in tumors due 
to their abnormally leaky vasculature. MPI images were quantified using a calibration 
curve to calculate iron contnent.66 
 
1.13 Limitations for Cell Tracking with MPI 
As described above resolution is currently one of the major limitations of MPI.  
Ongoing development of MPI tailored SPIOs should improve resolution. A second 
limitation is the requirement to acquire images with another imaging modality to obtain 
anatomical information. This can be done by co-registering the MPI images with images 
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obtained from CT or MRI. A MomentumTM MPI/CT system is now available. Limitations 
and challenges specific to this project are described in Chapter 4. 
 
1.14  Purpose of Thesis 
The purpose of this thesis was to use MPI for tracking MPIO labeled breast cancer 
cells that are dispersed in the mouse brain. MPI cell tracking using MPIO has not yet been 
studied. Our previous work using MRI to track MPIO-labeled cancer cells in the mouse 
brain has motivated these experiments. Although MPIO particles are very different from 
the SPIOs that have been used so far for MPI cell tracking our preliminary evaluation of 
MPIO showed favorable MPI characteristics (Chapter 2). MPIO particles also have very 
high iron content per particle compared to other commonly used SPIOs which could 
enhance cell detection sensitivity. We expect that MPI will provide complementary 
information to MRI for cancer cell detection, most significantly MPI will provide 
quantitative information on iron content and cell number. Our hypothesis is that MPI can 
be used for quantitative MPI of MPIO labeled cells arrested in the mouse brain.  
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Chapter 2  
2 Introduction 
This section contains a description of experiments conducted to test the precision 
of the MPI system and the magnetic properties of MPIO and Vivotrax. This was done to 
characterize these iron oxide particles before deciding if their use would be beneficial to 
cell tracking applications of breast cancer cells that have metastasized to the brain. Iron 
oxide particle characterization gave us information about expected MPI signal sensitivity 
and resolution from relaxometry testing. We were also able to create calibration lines for 
each iron oxide particle to use for iron content quantification from our in vitro MPI scans. 
This section also looks into the repeatability and reproducibility of the MPI system to test 
for uncertainty. This was explored by comparing results from three different users who 
imaged the same samples over three days to test reproducibility. Testing also included 
scanning the same sample multiple times and comparing iron measurements to also 
determine repeatability. We also explore how changing the number of averages used while 
scanning can help to detect low cell numbers in vitro as well as look into how MPI scans 
can affect cell viability. The methods and results from each experiment have been 
combined together in the following sections. 
 
2.1  Instrumentation 
2.1.1 The MomentumTM MPI System 
Magnetic Insights MomentumTM MPI system was installed at Robarts Research 
Institute August of 2019 (Figure 2.1). This installation marked Canada’s first MPI scanner. 
The maximum gradient magnetic field strength is 6.1 T/m. There are 2 transmit channels 
(X, Z), and 2 receive channels (X, Z) in which samples can be scanned with. The MPI 
system comes equipped with a digital camera above the sample bed to provide photographs 
against which the MPI images can be overlayed for rough anatomical reference. The 
sample bed comes with cut outs where reference tube markers can be placed to help with 
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co-registration and for insertion of tubing for gas anesthesia and vacuum lines. The 
maximum FOV is 12 cm x 6 cm x 6 cm. 
 
 
Figure 2.1: Photo of the MomentumTM MPI system from Magnetic Insight Inc. at Robarts Research Institute. (B) Photo 
of the sample bed of the MPI system with a sample placed at the 2 cm mark. 
 
2.1.2 Scan Modes 
There are six scan modes that can be selected from when conducting MPI scans 
(Table 2.1). The settings for acquisition parameters used to achieve each of these scan 
modes are hidden to the user and not accessible. This is meant to make the system user-
friendly and turn-key. The scan mode chosen will largely depend on the application you 
are using the MPI for. They include: (1) Default: this mode has a moderate scan time, and 
provides images with compromise resolution and sensitivity, used for many different 
applications. Preview: this mode is used for localizer or scout scans. It is the fastest 
acquisition scan but comes with the cost of both low sensitivity and resolution. It is 
typically used first for all imaging sessions. High Sensitivity: this mode is used when 
expecting low signal (close to detection limit). Higher sensitivity is obtained at the cost of 
low image resolution. High Resolution: this mode is used when higher resolution is needed. 
This is obtained at the cost of acquisition time and low sensitivity. Isotropic: this mode is 
A 
B 
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used when isotropic resolution is desired. The acquisition time is the slowest of all the scan 
modes as the scan is done with dual channel transmit/receive along X and Z. 
 
 
 
Table 2.1: Table summarizing the different MPI scan modes and the kind of performance that can expected with each 
mode. 
 
 
2.2 Methods and Results 
2.2.1 Iron Oxide Particles 
MPI is a tracer driven imaging technique and yet there are currently no 
commercially available MPI dedicated tracers. The most commonly used iron particle for 
MPI is ferucarbotran, originally a MRI contrast agent known as Resovist, and now made 
available as Vivotrax by Magnetic Insight Inc. In this thesis we analyzed the MPI 
characteristics of Vivotrax, since it is currently the benchmark against which other iron 
particles for MPI are compared, and MPIO since this iron particle is the focus of the thesis.  
 Vivotrax is a polydisperse mixture of particles containing both single iron cores (~ 
5 nm) and clusters of multiple cores (effective core size ~25 nm), leading to a bimodal size 
distribution (illustrated in Figure 1.8). Only the larger clustered particles are thought to 
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contribute to the MPI signal.67  MPIO are micron-sized iron oxide particles called Bangs 
Beads (also referred to as magnetic microspheres) from Bangs Laboratories Inc, Fishers, 
IN, USA. The MPIO used in this thesis have a mean hydrodynamic size of 0.9 μm and a 
broad size distribution (0.5 to 2 μm). These MPIO have many small iron cores (5 - 10 nm) 
embedded in a polystyrene matrix; the effective core size is larger but has not been 
determined experimentally. Appendix A contains electron microscopy images, gathered 
from manufacturers or published manuscripts, for Vivotrax, MPIO and other commercially 
available particles used for MPI. 
2.2.2 Relaxometry  
The MomentumTM MPI system at Robarts comes equipped with what is called a 
RELAX module. This module allows users to characterize SPIOs of interest. As described 
in 1.11 the RELAX module allows for measurements of the FWHM (spatial resolution) 
and signal per gram of iron (sensitivity) for individual SPIO.  
Relaxometry was performed for MPIO and Vivotrax. Samples of each were made 
by diluting the iron particle solution in PBS so that the samples contained the same amount 
of iron (30 mg), and each sample was scanned separately. The RELAX data takes 
approximately one minute to acquire per sample. This data is shown in Figure 2.2. The 
amplitude of the MPI signal for MPIO was higher than Vivotrax; the relative sensitivity 
was 1.5 for MPIO versus 1.0 for Vivotrax. The FWHM was larger for MPIO; the resolution 
of MPIO was 2.7 times that of Vivotrax; 4.49 mm versus 1.69 mm for a 6.1 T/m gradient. 
These preliminary results showed that MPIO could be a suitable SPIO for further MPI 
experiments, with high sensitivity, albeit relatively low resolution.  
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Figure 2.2: (A) Point spread functions (PSF) for MPIO and Vivotrax samples of 30 mg iron. MPIO has a higher peak 
signal indicating higher sensitivity. (B) MPIO has a larger full width at half maximum (FWHM) indicating poorer 
resolution compared to Vivotrax. (C) MPI image of MPIO sample containing 30 mg iron and (D) Vivotrax with 
corresponding PSF to the right of the images. 
 
2.2.3 Measuring the MPI Signal and Calibration for SPIOs 
To convert the total MPI signal to iron content requires a calibration. The 
relationship between MPI signal and iron content can be determined by measuring the MPI 
signal from a series of diluted samples of known iron content. The same type of SPIO and 
the same scan mode which will be used for the imaging experiment must be used for the 
acquisition of images for the calibration. The MPI signal is measured from the image of 
each sample and a calibration line is constructed by plotting the MPI signal for each sample 
versus the known values for iron mass in each sample. Subsequently, the equation of this 
line can be used to determine the iron content associated with MPI signal measured from 
an ROI. 
In this thesis calibration lines were made for MPIO and Vivotrax with different 
scan modes depending on the experiment. Samples of either Vivotrax or MPIO were 
diluted in PBS into aliquots of 100%, 75%, 50%, 37.5%, 25%, 10%, 7.5%, 5%, 3.75%, 
2.5% of iron. 1μL of each dilution was then pipetted into capillary tubing and 5 samples at 
B. Resolution A. Sensitivity C. MPIO 
D. Vivotrax 
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a time were spaced 2 cm from each other on the MPI sample bed to be imaged. The FOV 
was 12  x 6 x 6 cm.  Representative images and calibration lines for MPIO and Vivotrax 
are shown in Figure 2.3. Linear correlations were conducted between MPI signal and iron 
content to determine Pearson’s correlation coefficient. The equation for each line (y = mx 
+ b; where m is the slope and b is the y-intercept) (shown below the plots) is used to 
determine iron content (x) from the MPI signal (y). 
 
 
Figure 2.3:  2D MPI images of a series of diluted samples of Vivotrax (A) and MPIO (B) used to create the calibration 
lines shown in (C) and (D).  The relationship between iron content and MPI signal is linear for both nanoparticles. 
Equations derived from the calibrations (shown above the plots) are used for calculating iron content in MPI images. 
 
 
B 
5.6 μg 
0.7 μg 0.35 μg 0.175 μg 
2.8 μg 1.4 μg 
A 
5.5 μg 2.75 μg 
1.375 μg 0.69 μg 0.343 μg 
11 μg 
MPI Signal = 715.00 * (Iron Content) 
MPI Signal = 735.56 * (Iron Content) C 
D 
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2.2.4 Repeatability and Reproducibility Measurement  
To measure the precision of our new MPI system we acquired data for MPIO and 
Vivotrax to assess repeatability and reproducibility. Repeatability measures the variation 
in measurements taken by a single instrument and/or person under the same conditions. 
Samples containing 5 μL of MPIO or Vivotrax mixed with 50 μL of PBS were prepared.  
The suppliers of Vivotrax (Magnetic Insight Inc.) and MPIO (Bangs Laboratories) indicate 
that the iron concentrations is 5.5 mg of iron/ml for Vivotrax and 2.8 μg of iron/ml for 
MPIO, this amounts to an expected value of 27.5 μg of iron for 5 μL of Vivotrax and 14 
μg of iron for 5 μL of MPIO.  
In the first experiment the samples were placed on the MPI sample bed at the 2 cm 
mark and scanned six times without moving. In the second experiment the same samples 
were again scanned six times at the 2 cm mark but between scans the sample was removed 
and then repositioned. In the third experiment the same samples were scanned six times 
without moving it after being placed at the 4 cm mark. All data was acquired in default 
mode. The images for these samples are shown in Figure 2.4 and for Vivotrax in Figure 
2.5.  
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Figure 2.4: (A) Six MPI scans of a MPIO sample scanned at the 2 cm mark on the MPI sample bed, shown in a full 
FOV. (B) Six MPI scans of a MPIO sample which was scanned and then removed from the scanner and repositioned at 
the 2 cm mark for each subsequent scan. (C) Six MPI scans of a MPIO sample which was scanned at the 4 cm mark on 
the MPI sample bed. 
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Figure 2.5: (A) Six MPI scans of a Vivotrax sample scanned at the 2 cm mark on the MPI sample bed, shown in a full 
FOV. (B) Six MPI scans of a Vivotrax sample which was scanned and then removed from the scanner and repositioned 
at the 2 cm mark for each subsequent scan. (C) Six MPI scans of a Vivotrax sample which was scanned at the 4 cm 
mark on the MPI sample bed. 
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For each image the total MPI signal was measured and the iron content calculated 
using calibration lines described in 2.2.2. The individual values for iron content and the 
average value and standard deviation of these measurements are shown in Table 2.2 for 
MPIO samples and Table 2.3 for Vivotrax for each experiment. The value for standard 
deviation reports on the variation in measurements and thus repeatability for these 
experiments. The smaller the number the lower the variability. Our results show that there 
was some variation in the measurements for all experiments. There was more variability 
for MPIO samples compared to Vivotrax.   
 
Table 2.2: Table summarizing the iron content measured from each MPIO sample that was scanned in Figure 2.4, the 
mean iron content of the 6 samples, and the standard deviation. 
 
 
Table 2.3: Table summarizing the iron content measured from each Vivotrax sample that was scanned in Figure 2.5, the 
average iron content of the 6 samples, and the standard deviation. 
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Reproducibility is most often defined as the degree of agreement between the 
results of experiments conducted by different individuals, or different location or 
instruments and measures whether an experiment can be reproduced. For measuring 
uncertainty in an instrument reproducibility can also be assessed by changing the 
conditions of the measurement for the same sample. In this case a measure of 
reproducibility can be made by performing a repeatability test, changing a variable and 
repeating the repeatability test (as done above), calculating the average values for each test 
and calculating the standard deviation of the test averages. This was calculated for 
experiment 1 versus 2 and experiment 1 versus 3 for MPIO and Vivotrax. The standard 
deviations were 1.05, and 0.42 for MPIO and 0.11, and 0.43 for Vivotrax. 
 
2.3 In Vitro MPI of SPIO-Labeled Cells 
2.3.1 Cell Labeling with SPIOs 
Our lab has been developing cell labeling techniques for many years and has 
experimented with a range of cell lines and SPIOs. In this thesis, MPIO and Vivotrax were 
the two SPIOs used for cell labeling. For cell culture, cells were maintained at 37°C and 
5% CO2 in Dulbecco’s modified Eagle’s medium (Gibco, Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) supplemented with 10% fetal bovine serum and 1% penicillin 
streptomycin antibiotic. Cells were passaged every 2-3 days to prevent overgrowing and to 
discard dead cells and debris. For cell labeling with MPIO, adherent cells were incubated 
with 25 μg Fe/mL of MPIO for 24 hours. Cells were then washed three times with Hanks 
balanced salt solution (HBSS) and then trypsinized with 0.25% Trypsin-EDTA. The cells 
were then collected and washed another three times with HBSS to remove unincorporated 
MPIO before being used.  
For cell labeling with Vivotrax we have seen that simple coincubation does not 
produce good labeling efficiency, therefore, labeling was enhanced by the use of 
transfection agents.  A labeling mixture is prepared using 2 falcon tubes of 2.5 mL of serum 
free DMEM. In tube A, 60 μL of stock protamine sulfate was added and vortexed to mix. 
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In tube B, 90 μL of Vivotrax was added and vortexed to mix. 20 μL of stock heparin was 
then added to tube B and then vortexed to mix. Old media was removed from cells and 
rinse once with HBSS. Tubes A and B were combined and vortexed. This labeling mix was 
added to the flask and incubated at 37°C, 5% CO2 for 2-4 hours. 5 mL of complete DMEM 
was added to the flask after the 2-4 hours and incubated at 37°C, 5% CO2 overnight. This 
protocol has been published by Arbab et al. and implemented for various cell types and 
SPIO in the Foster lab.2 On day 2 cells were washed 3 times with HBSS and then 
trypsinized with 0.25% Trypsin-EDTA. The cells were then collected and washed another 
three times with HBSS to remove unincorporated Vivotrax before being used. For both 
labeling methods, cell viability after labeling was assessed using the trypan blue exclusion 
assay and labeling efficiency was assessed by staining for iron with Perl’s Prussian blue 
(PPB) and subsequently counting the number of positively stained cells in 3 random 40x 
magnification fields under the microscope. Representative PPB images of MPIO and 
Vivotrax labeled cells are shown in Figure 2.6.  
 
 
Figure 2.6: (A) Representative Perl’s Prussian Blue (PPB) staining of MDA-231-BR cells labeled with (A) MPIO and 
B) Vivotrax shown at 40x magnification. 
 
2.3.2 Reproducibility for MPI of Cell Samples 
Reproducibility was also assessed by scanning MPIO-labeled cell samples on three 
separate days by 3 different MPI users. This looked at both variations in the measurements 
of the same samples on different days, and at variations in the quantification of images by 
A B 
 
 
 
44 
 
different users.  Cell samples were created by co incubating MDA-231-BR cells with 25 
μg Fe/mL of MPIO particles. Three samples were made each containing 2.5 x 105 MPIO 
labeled MDA-231-BR cells. Each user scanned the three samples three times, three days 
in a row. Images were acquired in 2D high sensitivity mode with a FOV of 12  x 6  x 6 cm, 
each sample was placed at the – 2cm center line.  
Each user individually quantified their data using the same quantification protocol 
and calibration line. Figure 2.7 shows all of the MPI scans along with the values for iron 
content measured from MPI. Table 2.4 shows the data for all measurements. The average 
values for iron content for each user are compared in Figure 2.8. There was no significant 
difference in these measurements day to day or from sample to sample for Users 1 and 2.  
The measurements from User 3 were significantly higher than Users 1 and 2. The higher 
values for User 3 may be  attributed to the user drawing a larger ROI area when measuring 
the mean MPI signal, which is used in the following equation to determine total MPI signal 
and subsequently iron content.  
 
MPI signal = Mean signal in ROI (A. U.) ∗ ROI volume (mm3 or mm2) 
 
When it comes to choosing the ROI the manual outlining of an ROI is user 
dependent and the signal interpreted as true signal may vary between users. A way to help 
mitigate this user variability is by having consistent protocols and training when it comes 
to teaching users best quantification practices. 
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Figure 2.7: MPI images of three samples of  2.5 x 105 MPIO labeled cells imaged on three different days and the iron 
content quantified by User 1 (A), User 2 (B), and User 3. (C). For each user there was no significant difference between 
the measurements made for e each sample on each day or for the measurements made between days. 
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Table 2.4: Table summarizing the iron content calculated for each sample that was scanned in Figure 2.7, the average 
iron content of the three samples scanned on each day and the standard deviation calculated by each user. 
 
 
 
Figure 2.8: The average iron content measured for the three cell samples by each user on each day of the experiment. 
**The values measured by User 3 were significantly higher than those measured for Users 1 and 2, on each day. 
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2.3.3 SPIO Labeled Cell Detection Limits  
To assess differences in the detection limits between MPIO and Vivotrax labeled 
cells we compared samples containing the same number of cells using the same MPI 
imaging parameters. Eighteen cell samples were prepared for each of the MPIO and 
Vivotrax labeled MDA-231-BR cells; three samples of six different cell numbers: 2.0 x 
105, 1.0 x 105, 5.0 x 104, 1.0 x 104, 5.0 x 103 and 2.5 x 103 cells. Each sample was scanned 
using the 2D High Sensitivity/Isotropic mode. The scan time for each sample was ~ 3 
minutes.  Representative images for one set of samples for each nanoparticle are shown in 
Figure 2.9. Images collected with no sample (empty bed) and no sample bed (empty bore) 
are provided to show the background noise level. The lowest cell number that could be 
detected clearly under these imaging conditions was 1.0 x 104 for both MPIO and Vivotrax 
labeled cells.  Images containing fewer cells were difficult to quantify as true signal was 
hard delineate from noise. The measured MPI signal for each cell number is shown in plots 
in Figure 2.10 and all data is presented in Table 2.5. To increase MPI sensitivity the number 
of signal averages was increased to 8 (~17 minutes) and the samples with the lowest cell 
number were scanned again. Scanning with 8 averages improved the detection of the cell 
sample compared to no averaging.  
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Figure 2.9: MPI images of MPIO (A) and Vivotrax (B) labeled cell samples with decreasing cell numbers. The white 
square indicates the position of the cell sample. The empty bed and empty bore scans show the background signal. 
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Figure 2.10: (A) Graphs showing the iron content measured from each cell sample scanned in Figure 2.9. The results 
show decreasing iron content with decreasing cell number and similar detection limits for MPIO and Vivotrax. 
 
 
Table 2.5: Table showing the iron content measured from each cell sample scanned in Figure 2.9. 
 
B A 
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Iron content measurements for both the MPIO and Vivotrax labeled cells were 
similar. This was unexpected since cells labeled with MPIO typically have a higher iron 
load than Vivotrax. The PPB staining of Vivotrax labeled cells could shed some light on 
this result. The use of transfection agents to enhance labeling with Vivotrax appears to lead 
to more extracellular iron and iron clumping and this may lead to an overestimation of iron 
in a cell sample. Future work will examine the impact of labeling with transfection agents 
more closely. 
This experiment was not meant to determine the minimum number of cells that 
could be detected, since this depends on imaging parameters and could be further improved 
with careful and systematic optimization of scan parameters. This experiment 
demonstrated how adjusting imaging parameters (i.e., increasing the number of averages) 
was able to improve MPI images where signal was originally difficult to detect. 
2.3.4 MPIO Labeled Cell Viability After MPI  
It is important to know if MPI affects cell viability. Since the technology is just 
emerging for cell tracking this had not been assessed before.  The main concern is that the 
magnetic particles release energy as heat when exposed to alternating magnetic fields.  The 
frequency (40 kHz) and excitation combination (20 mT) used by MPI are designed to be 
low enough not to increase temperature, however it is difficult to know how hot the surface 
temperature of a particle gets in comparison to tissue level.  The other concern is that the 
alternating and moving fields cause the particles to physically rotate and this could 
potentially cause cellular damage.   
Six cell samples were prepared. Three samples were scanned separately, and three 
samples served as control samples (no MPI). A trypan blue exclusion assay was first 
conducted on both the control samples and the samples that were going to be scanned by 
MPI. This was done by taking 10 μL of the cell solution and mixing it with 10 μL of the 
trypan blue dye. The mixture was pipetted into a cell counting chamber slide and inserted 
into the CountessTM. Cell viability is reported as the percentage of stained cells. The labeled 
cancer cells then underwent a 2D high sensitivity MPI scan (about a 1 minute scan). The 
trypan blue exclusion assay was then repeated again on both the control and MPI scanned 
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samples. The samples had 90-93% cell viability before MPI scans and 88-90% cell viability 
after MPI scanning. Figure 2.11 shows a plot of the cell viability for all the control and 
MPI samples. There was no significant difference in % viability between MPI samples 
before and after being scanned. There was also no significant difference between control 
and MPI sample before as well as control and MPI samples after. There was however a 
significant difference in % viability between control before and after values.  
 
 
Figure 2.11: Graph showing the percent viability between control and MPI scanned samples of MPIO labeled cells 
before and after MPI scans. The viability for control samples was 90-93% before and 88-89% after the experiment. The 
viability for samples scanned by MPI was 90-93% before and 89-90% after the experiment. There was no significant 
difference in viability before and after the experiment of MPI samples and no significant difference in viability when 
comparing control and MPI scanned samples. However, there was a significant difference in control % viability before 
and after.  
 
2.3.5 Statistical Analysis 
Simple linear regression was used to evaluate the relationship between total MPI signal 
and iron content and to create equations used for iron content quantification and the 
goodness of fit R2 value.  Repeatability and reproducibility data are presented as mean +/- 
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standard deviation; a 5% difference was deemed as good reproducibility. The data which 
compared measurements from 3 different MPI users used a repeated measures one-way 
ANOVA to determine statistical significance for each of the following: a) between samples 
from each user, b) between days for each user and c) iron values between all the users. 
Simple linear regression was performed on the cell detection data to determine the 
relationship between MPI signal and cell number represented by the R2 value. A paired t-
test was performed on the MPI viability data to determine statistical significance between 
control samples at the before and after time points. Another paired t-test was performed on 
the MPI samples before and after the MPI scan. Welch’s t-tests were done between all 
‘before samples’ and all ‘after samples’ to determine statistical significance. These 
analyses were conducted using Prism software (8.0.2, GraphPad Inc.), where p <0.05 was 
considered statistically significant. 
 
2.4 Discussion 
Relaxometry was performed on both MPIO and Vivotrax to provide information 
on the magnetic properties, and MPI performance, of these particles. This data provided 
values for resolution and sensitivity for each particle. The amplitude of the MPI signal for 
MPIO was higher than Vivotrax; the relative sensitivity was 1.5 for MPIO versus Vivotrax. 
The FWHM was larger for MPIO with a resolution 4.49 mm versus 1.69 mm for Vivotrax. 
This showed that MPIO could potentially be a suitable SPIO for MPI experiments. We 
continued to compare MPIO to Vivotrax in further experiments. 
When we first started quantifying iron from MPI images we used a method that 
used a reference tube with a known amount of the SPIO, that was scanned alongside a cell 
sample or mouse in the same FOV. The signal from the subject of interest could then be 
compared to the signal from the reference tube to determine iron content. This was not 
always a reliable method as sometimes signal from the reference tube would interfere with 
the signal of interest because the iron content in the reference tube was greater than the 
iron in the sample. Trying to estimate how much iron is in the sample or subject being 
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imaged, so that the iron content in  the reference tube was similar is challenging since it is 
usually not known, especially when scanning mice in vivo.  
The use of a calibration line for quantifying iron content from MPI data was 
developed in our lab, in collaboration with Dr. Ashley Makela a former PhD student in the 
Foster lab, now using MPI as a postdoctoral fellow at Michigan State University. 
Calibration lines could be made after an imaging session based on the exact scanning 
parameters and a range of dilutions and produced fewer variable results. Calibration lines 
were made for MPIO and Vivotrax with different scan modes depending on the experiment. 
Samples of either Vivotrax or MPIO were diluted in PBS into aliquots before being 
scanned. This method was used to quantify all the iron content data in this thesis and is 
now used routinely in our lab for all other MPI experiments. 
Repeatability tests were conducted on the MPI system to determine how variable 
the data acquisition and analysis of data was. In experiment 1, samples were scanned six 
times without being removed from their position on the MPI bed. Those same samples 
were then taken out and placed back in the MPI bed, in between individual scans, for 
another round of six scans. Lastly, the samples were placed at the 4 cm mark on the MPI 
and scanned six times without being moved. Results showed that there is some variation in 
the measurements for all experiments. For assessing the precision of a new instrument, the 
manufacturers (in this case Magnetic Insight Inc.) consider 5% signal change to be the 
acceptable variation for a sample (100% Vivotrax) scanned repeatedly. Our data was not 
always within this range. The variability was less for the Vivotrax data compared to the 
MPIO data. This could be related to clumping of the larger MPIO particles. Recent data 
acquired by other students in the lab has indicated that vortexing of samples immediately 
prior to scanning changes the MPI signal. For MPIO the variability was lowest when the 
sample was at the 2 cm mark and not moved in between scans.  The ‘true’ iron content for 
the Vivotrax sample (determined using manufacturer’s stated iron concentration) was 27.5 
μg and the mean values measured for the three conditions were 28.5, 28.9 and 29.0, which 
are within 6% of the true value. For the MPIO sample, the iron content was 14 μg and the 
mean values for the three conditions were 17.4, 19.5 and 20.3, which are farther off. 
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Reproducibility was tested by having 3 different MPI users scan and analyze the 
same sample of 2.5 x 105 cells that were MPIO-labeled. Results showed that even though 
these users were analyzing the same sample using the same quantification methods there 
was some variability in iron mass calculated. While user 1 and 2 results were not 
significantly different user 3’s results were significantly different from user 1 and 2. This 
is likely due to the fact that there is subjectivity when it comes to the amount of signal 
included in the ROI that is manually drawn by each individual user. Some may choose to 
include more signal than the other. This can also influence the values for MPI signal and 
area or volume which are used to calculate iron content.  
Cell detection limits were also explored using MPIO or Vivotrax labeled cell 
samples ranging from 2.5 x 105  to  2.5 x 103 cells and scanned using the 2D high sensitivity 
isotopic mode. For both MPIO and Vivotrax, images of samples which contained fewer 
than 1.0 x 104 cells showed increasing signal in the background and made it more 
challenging to detect and quantify the MPI signal. For the samples with the lowest cell 
number (2.5 x 103) a 2D high sensitivity isotopic scan with 8 averages was also acquired 
to determine whether this approach would improve the signal and enhance detection. On 
the MomentumTM MPI system the projection images are acquired as 2D panels which are 
then stitched together to form the entire image. The overlap fraction is how much these 
panels overlap each other and are best thought of as a method of averaging.  In this case a 
higher overlap fraction results in more signal averages and more signal for higher 
sensitivity; the trade-off is scan time. The scan time for images acquired with no averaging 
was 3 minutes, with 8 averages the scan time was 17 minutes. The relationship between 
signal averaging, via overlap fraction, and sensitivity has not been well studied. 
These results showed how adding additional averages could be utilized to improve 
MPI image quality it comes with the trade-off of increased scan time from ~3 minutes with 
1 average to ~17 minutes with 8 averages. 
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Chapter 3  
3 Superparamagnetic microspheres can be used for 
magnetic particle imaging of cancer cells arrested in the 
mouse brain 
The work in Chapter 3 was submitted as a manuscript to Magnetic Resonance in 
Medicine in September 2020. It has come back with requests for revisions and will be 
resubmitted by December 2020. For Chapter 3, some additional data has been added to the 
manuscript.  
 
3.1 Introduction 
Cellular MRI combines the ability to obtain high-resolution MRI data with the use 
of magnetic contrast agents for labeling specific cells, thereby enhancing their 
detectability.1,2 The most widely used cell labeling agents for cell tracking are magnetite 
(Fe3O4)-based super paramagnetic iron oxide (SPIO) nanoparticles. Commonly used iron 
oxide nanoparticles consist of a small (< 10 nm) iron oxide crystal core covered by a 
dextran coating bringing the total hydrodynamic size of the particles to approximately 20-
50 nm (ultrasmall, USPIO) or 60-150 nm (standard, SPIO), respectively. Micron-sized iron 
oxide particles (MPIO) have also been used for preclinical cell tracking studies. MPIO are 
superparamagnetic microspheres with multiple small iron crystals (5-10 nm) distributed 
throughout a polymer matrix that are relatively large (0.9 – 1.63 μm hydrodynamic size). 
Of the SPIO used for MRI cell tracking, MPIO have the highest iron content per particle, 
approximately 1pg Fe/particle which is roughly equivalent to 1.5 million standard SPIO 
particles or 4 million USPIO.3 The presence of SPIOs causes a distortion in the magnetic 
field and leads to signal hypo-intensities in iron-sensitive images (T2- and T2*-weighted 
images are most often used). Areas containing SPIO-labeled cells appear as regions of low 
signal intensity (signal voids) on MRI images, creating negative contrast. Many different 
cell types have been pre-labeled with iron particles and tracked with MRI, including 
mesenchymal stem cells,4,5 progenitor cells,6 dendritic cells,7-9 cancer cells10-12 and 
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pancreatic islets13. This technique is highly sensitive, permitting the imaging of single cells 
in vivo14,15, under ideal conditions.  
There are, however, several limitations of iron-based MRI cell tracking. The first 
is low specificity due to other low-signal regions in T2/T2* images, i.e., SPIO-labeled cells 
in the lung or in a region of hemorrhage cannot be detected. Although ultra-short echo time 
imaging methods have been developed for producing positive contrast from iron-labeled 
cells these too have similar problems with specificity.16 Second, quantification of iron-
induced signal loss is complicated. Our group and others have shown that the degree of 
signal loss produced by SPIO-labeled cells is only linear at low iron concentrations.17 
Typically, the degree of contrast (how black is it) or the volume of signal loss (how big a 
void is there) is measured from these images. Although some studies have used MR-based 
relaxometry to show a linear relationship between R2*values and SPIO-labeled cell 
concentration in samples18 the in vivo cell quantification by this method is more 
complicated.  Overall, with iron-based MRI cell tracking there are issues with specificity 
and iron-labeled cell number cannot be accurately determined. 
Magnetic Particle Imaging (MPI) is a new imaging modality that directly detects 
SPIOs.19,20 MPI cell tracking may address the limitations presented by SPIO-based cell 
tracking. First, the MPI signal is only generated when the magnetic moments of the SPIOs 
rotate; this change in magnetization is in response to the application of an excitation field 
and is localized only to the SPIO within a region devoid of a magnetic gradient. This results 
in positive “hot-spot” contrast that provides spatial localization without ambiguity. This is 
because there is no signal from within the subject as biological tissues neither generate nor 
attenuate MPI signals. Second, the MPI signal is linearly quantitative with iron 
concentration, and therefore the number of SPIO labeled cells can be directly calculated. 
The sensitivity of MPI derives from the direct detection of the electronic magnetization of 
SPIO, which is 108 times larger than the nuclear magnetization of protons seen in MRI.21 
This translates to a theoretical MPI sensitivity in the hundreds of cells with current 
hardware and available SPIO. The highest cell detection sensitivity to date was reported to 
be 250 cells in vivo.22  
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The ideal SPIOs for MPI are still not known. Both MPI sensitivity and resolution 
are closely related to the physical properties of a SPIO. The resolution of MPI is driven 
primarily by the interaction of the nanoparticle and the magnetic field gradient.  Theoretical 
modeling predicts that resolution improves with increasing core size.23 However, this has 
not always been observed experimentally. The sensitivity of MPI depends on both 
nanoparticle and scanner specific factors.  Nanoparticle factors include the strength of the 
nanoparticle magnetization (the greater the magnetization the greater the MPI signal and 
therefore higher sensitivity) and the efficiency of the nanoparticle cell labeling (more iron 
per cell leads to higher sensitivity).  
Currently the most commonly used SPIO for MPI has been a commercially 
available agent, Vivotrax from Magnetic Insight Inc. (USA). VivoTrax is a Ferucarbotran 
with multi-core/aggregated particles and coated with carboxy-dextran. Vivotrax has been 
used in MPI studies of mice to detect mesenchymal stem cells24,25, neural stem cells26, 
neural progenitor cells27, pancreatic islets28, T-cells29, and macrophages.30,31 
Our lab has previously used MPIO to label metastatic cancer cells for detection in 
the mouse brain by MRI.  In our previous studies MPIO-labeled cancer cells were 
administered via intra-cardiac injection which results in their arrest throughout the brain 
vasculature as individual cells or clusters of small numbers of cells. The high cellular iron 
loading created when labeling cells with MPIO (20-30 pg of iron/cell) permitted the 
detection of single cells in vivo by MRI.10 At this time there are no published reports of the 
use of MPIO-labeled cells for their in vivo detection by MPI. Therefore, the goal of this 
study was to evaluate if MPIO can be used for in vivo detection and quantification of cancer 
cells distributed in the mouse brain by MPI.   
 
3.2 Methods 
3.2.1 Iron Oxide Nanoparticles Relaxometry 
 Two types of iron oxide nanoparticles were used in these studies: (i) Vivotrax 
(Magnetic Insight Inc, Alameda, CA, USA) and (ii) MPIO (Bangs Laboratories Inc, 
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Fishers, IN). The particle relaxometer module (RELAX) on the MomentumTM MPI system 
(Magnetic Insight Inc., Alameda, California) was used to characterize MPIO and Vivotrax 
(30 mg Fe for each). In this mode, the localizer gradient field is switched off and a negative 
magnetic field is turned on and then switched to a positive field (and vice versa). As a 
result, iron nanoparticles are driven from a negative magnetic saturation to positive 
(positive scan) and vice versa (negative scan). This measures the point spread function 
(PSF) of the nanoparticles and allows for measurements of the MPI signal per iron content 
(sensitivity) and full-width half-maximum (FWHM; spatial resolution). A narrower tracer 
response indicates superior spatial resolution and a greater signal intensity per unit iron 
indicates superior sensitivity. 
3.2.2 Calibration Line Preparation 
Calibration lines were generated for use in quantifying iron content in brains after 
iron-labeled cell injection. To construct each line, samples of each nanoparticle were 
scanned in the same mode as images being analyzed (In vivo = 3D isotropic, ex vivo = 2D 
default). Samples of either Vivotrax or MPIO were diluted in PBS into 100%, 75%, 50%, 
37.5%, 25%, 10%, 7.5%, 5%, 3.75%, 2.5% aliquots. 1μL of each dilution was then pipetted 
into capillary tubing and spaced out 2 cm from each other on the MPI sample bed to be 
imaged, 5 samples at a time. The field of view (FOV) was 12 x 6 x 6 cm.  
3.2.3 Cell Culture and Labeling 
Two cancer cell types with similar growth characteristics were used in these 
studies: (i) human MDA-231-BR brain metastatic breast cancer cell line and (ii) murine 
4T1BR5 metastatic breast cancer cell line.  Both cell lines were maintained at 37°C and 
5% CO2 in DMEM (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin antibiotic. 
Cells were passaged every 2-3 days. For cell labeling with MPIO, adherent cells were 
incubated with 25 μg Fe/mL MPIO beads for 24 hours. Cells were washed three times with 
Hanks balanced salt solution (HBSS) and then trypsinized with 0.25% Trypsin-EDTA. The 
cells were then collected and washed another three times with HBSS to remove 
unincorporated MPIO before cell injection and in vitro evaluation. For cell labeling with 
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Vivotrax, cells were grown for 2-4 days until they reach 80-90% confluency. A labeling 
mixture was prepared using 2 falcon tubes of 2.5 mL of serum free DMEM. In tube A, 60 
μL of stock protamine sulfate was added and vortexed to mix. In tube B, 90 μL of Vivotrax 
was added and vortexed to mix. 20 μL of stock heparin was then added to tube B and then 
vortexed to mix. Old media was removed from cells and rinse once with HBSS. Tubes A 
and B were combined and vortexed. This labeling mix was added to the flask and incubated 
at 37°C, 5% CO2 for 2-4 hours. 5 mL of complete DMEM was added to the flask after the 
2-4 hours and incubated at 37°C, 5% CO2 overnight. On day 2 cells were washed 3 times 
with HBSS and then trypsinized with 0.25% Trypsin-EDTA. The cells were then collected 
and washed another three times with HBSS to remove unincorporated Vivotrax before cell 
injection and in vitro evaluation. This approach for cell labeling is what we routinely do 
for labeling cells with ferumoxytol nanoparticles (i.e., Feraheme) and was used in this 
study for cell labeling with Vivotrax because cells could not be labeled efficiently with 
simple co-incubation, as they could be with MPIO. In both scenarios, cell viability after 
labeling was assessed using the trypan blue exclusion assay and labeling efficiency was 
assessed by Perl’s Prussian Blue (PPB) staining by counting the number of positively 
stained cells in 3 random 40x magnification fields under the microscope. 
3.2.4 Mouse Model 
Female nude (nu/nu) (6-8 weeks; Charles River Canada or USA) or NSG 
(NOD/SCID/ILIIrg-/-)  mice  were obtained and cared for in accordance with the standards 
of the Canadian Council on Animal Care, under an approved protocol by the Animal Use 
Subcommittee of Western University’s Council on Animal Care and Use Committee. Mice 
were anesthetized with isoflurane administered at 2% in oxygen and iron-labeled cancer 
cells were injected intracardially into the left ventricle of the heart under ultrasound 
guidance using a Vevo 2100 ultrasound system (Visual Sonics Inc.). The delivery of cells 
to the brain after intracardiac injection is related to the cardiac output, with only 15-20% 
of cardiac output reaching the brain. Based on this, we estimate that a similar percentage 
of iron-labeled cells will be initially delivered to the brain with a technically accurate 
injection. In our previous studies which have used intracardiac injection of iron-labeled 
cells to study brain metastasis, MRI is performed on the same day of the injection to verify 
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delivery of cells to the brain. We have demonstrated that the number of signal voids, caused 
by iron-labeled cells, increases with the number of cells injected. When considering cell 
detection sensitivity for MPI it is worth noting that cells injected this way will be 
distributed throughout the entire brain, not in a similar region all together.  
Experiment 1 (ex vivo MPI):  Mice received an intracardiac injection of either 
2.5 × 105 (n=2, ~50,000 cells in brain) or 5 × 105 (n=2, ~100,000 cells in brain) MPIO-
labeled 231BR cells in 0.1 mL of HBSS.  One mouse from each group was imaged with 
MRI in vivo (as described below) on the day of the injection (day 0) and then the mice 
were euthanized, and the fixed mouse heads were shipped to Michigan State University 
(East Lansing, MI) to be imaged with MPI on a MomentumTM MPI system by co-author 
AM. At this time, we did not have an MPI system installed at Robarts Research Institute. 
The goal of this preliminary experiment was to determine if MPIO-labeled cells could be 
detected in this mouse brain model system. MPI data was acquired with default 2D scans 
using a 4 x 6 x 6 cm FOV and a 5.7 T/m gradient.  
Experiment 2 (in vivo MPI):  Mice received an intracardiac injection of either  
2.5 × 105  (n=3, ~50,000 cells in brain) or 5 × 104 (n=3, ~10,000 cells in brain) MPIO-
labeled 231BR cells in 0.1 mL of HBSS.  These mice were imaged in vivo on the day of 
the injection (day 0) with MRI to verify the success of the cell delivery to the brain and 
then MPI on a MomentumTM MPI system at Robarts Research Institute. 3D images were 
acquired using a 3 T/m gradient, 35 projections and a FOV 12 x 6 x 6 cm, with a total scan 
time ~1 hour per mouse (the 3D high sensitivity mode on the MomentumTM system). 
Experiment 3:  Mice received an intracardiac injection of 5 × 104 Vivotrax- or 
MPIO-labeled 4T1BR5 cells (n=4 per group, ~10,000 cells in brain).  Mice were imaged 
in vivo on the day of the injection (day 0) with MRI to verify the cell injection and MPI, 
as in experiment 2. 
MPI images were analyzed utilizing Horos imaging software. (Horos is a free and 
open source code software program that is distributed free of charge under the LGPL 
license at Horosproject.org and sponsored by Nimble Co LLC d/b/a Purview in Annapolis, 
MD USA).  Images were displayed in full dynamic range and total MPI signal was 
 
 
 
62 
 
calculated. Areas of interest from 3D images were manually outlined, slice by slice, 
creating a 3D volume. In 2D images, the areas of interest were manually outlined in a single 
slice. The mean signal from these ROI’s were then multiplied by the ROI volume/area to 
determine the total MPI signal. For the nanoparticle samples the total MPI signal (y) was 
plotted against iron content to (x) derive the calibration lines. This relationship was used 
to quantify iron content (x) in mouse brains. Where the total MPI signal was substituted 
for y, (m) is the slope of the line and (b) is the y-intercept in y= m x +b. All MPI images 
were analyzed in the same way to ensure consistency.  
3.2.5 Magnetic Resonance Imaging  
In vivo proton (1H) MRI for all mice was performed at 3 Tesla using a GE MR750 
system equipped with an insertable gradient coil and a solenoidal mouse head 
radiofrequency coil. While imaging, mice were anesthetized with 2% isoflurane in oxygen. 
A 3D balanced steady state free precession pulse sequence was used. Image resolution was 
200 x 200 x 200 μm and sequence parameters were as follows: FOV = 1.5 cm  x 1.5 cm, 
matrix = 150 x 150, flip angle = 35°, receiver bandwidth = +/-41.67  kHz, repetition 
time/echo time (TR/TE) = 4.2/2.1 ms, 2 signal averages and 8 phase cycles resulting in a 
scan time of ~30 minutes. 
MRI data was also visualized and analyzed using Horos imaging software. For 
experiment 1 brain images were assessed for the presence of signal voids attributable to 
iron-labeled cells arrested in the mouse brain vasculature after the intracardiac injection. 
Iron-labeled cells in the brain were quantified by determining the percentage of black pixels 
by drawing a region of interest (ROI) around the whole brain and setting a threshold value 
based on the mean signal intensity value of a signal void ± 2 standard deviations. The total 
number of black pixels below this threshold value was obtained from the entire brain 
volume signal intensity histogram. The number of black pixels was divided by total number 
of pixels to calculate the percentage of black pixels. 
3.2.6 Statistical Analysis 
Data are presented as mean +/- standard deviation in experiment 2 to compare the 
amount of iron content measured in the brains of mice injected with 2.5 x 105 cells and the 
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brains of mice injected with 5.0 x 104 cells. Simple linear regression was used to evaluate 
the relationship between total MPI signal and iron content to create equations used for iron 
content quantification and the goodness of fit R2 value. These analyses were conducted 
using Prism software (8.0.2, GraphPad Inc.), where p <0.05 was considered statistically 
significant.  
 
3.3 Results 
3.3.1 Evaluation of Vivotrax and MPIO Performance by 
Relaxometry and MPI 
The relaxometer mode on the MPI system was used to compare the performance of 
MPIO to Vivotrax. This data is shown in Chapter 2 in Figure 2.2.  The amplitude of the 
MPI signal for MPIO was slightly higher than Vivotrax; the relative sensitivity was 1.5 for 
MPIO versus 1.0 for Vivotrax. The FWHM was wider for MPIO; the resolution of MPIO 
was more than 2.5x that of Vivotrax; 4.5 versus 1.7 mm for a 6.1 T/m gradient.  
Figure 3.1 shows an example of the images of MPIO and Vivotrax samples 
measured to generate the calibration lines. Ten samples were scanned for each SPIO, 5 
samples were scanned at a time. This allowed for proper spacing between samples so that 
the signals did not overlap. The images are displayed in full dynamic range so all samples 
are visible, which is why the samples with the lowest 5 iron contents appear to have signal 
as strong as the highest 5 iron contents. 
 There was a strong linear relationship between iron content and MPI signal 
(arbitrary units, A.U.) for both MPIO (R2 = 0.9498, P < .0001) and Vivotrax (R2 = 0.9938, 
P < .0001).  The equation of the line was: MPI Signal = 24.32 * (Iron Content) + 2.507 for 
MPIO and MPI Signal = 20.57* (Iron Content) + 0.8914 for Vivotrax. Using this 
relationship, iron content could be determined for a given MPI signal in subsequent 
imaging experiments.  
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Figure 3.1: (A) 3D low resolution MPI images of a series of diluted samples of MPIO (B) and Vivotrax (C) used to 
create the calibration lines shown in (D) and (E).  Images are scaled so that all samples are visible. The relationship 
between iron content and MPI signal is linear for both nanoparticles. Equations derived from the calibrations are used 
for calculating iron content in MPI brain images. 
 
3.3.2 Imaging 
PPB staining confirmed the successful labeling of cancer cells with either MPIO or 
Vivotrax (shown previously in Figure 2.6). Labeling efficiency was greater than 90% for 
MPIO and 70% for Vivotrax. Labeling with either nanoparticle did not change cell 
viability; > 95% before and after labeling. Figure 3.2 A shows in vivo MRI of mice injected 
B 
MAX 
MIN 
    2 cm 
 2.8  μg    2.1 μg    1.4 μg   1.05 μg    0.7 μg 
0.28 μg  0.21 μg  0.14 μg  0.105 μg  0.07 μg 
C 
 5.5 μg   4.13 μg    2.75 μg   2.06 μg    1.38 μg 
MAX 
MIN 
  0.55 μg  0.41 μg   0.28 μg     0.21 μg  0.14 μg  
D 
MPI Signal= 24.32 *(Iron Content) + 2.570 MPI Signal= 20.57*(Iron Content) + 0.8914 
    2 cm 
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with 5 × 105 cells or Figure 3.2 B with 2.5 × 105. Ex vivo MPI images from experiment 1 
for all 4 mice injected with either 5 × 105 (Fig 3.2 C & E; n=2) or 2.5 × 105 (Fig 3.2 D & 
F; n=2) MPIO-labeled 231BR cells. One mouse from each group was imaged in vivo with 
MRI. MR images showed the characteristic signal voids throughout the brain (3.2 A & B) 
representative of iron-labeled cells arrested in the brain on the day of the intra-cardiac 
injection, consistent with numerous previous MRI studies conducted in our lab. MPIO-
labeled 231BR cells were detected by MPI in all fixed brains. MRI and MPI images are 
both presented in the coronal plane. Quantification of the MRI and MPI data is shown in 
Table 3.1. The signal voids were quantified by measuring the percentage of black pixels in 
the whole brain. These values were 1.04% for the 2.5 × 105 cell injection and 2.77% for the 
5 × 105 cell injection.  The iron content measured by MPI ranged from 2.39 to 3.32 μg of 
iron per brain. The iron content measured in mouse 3 was similar to that of mouse 1 and 2 
which received a higher number of cells. In the images reference tubes can be seen which 
can be used for quantification and co-registration purposes. However, for this analysis we 
used the calibration lines for quantification instead. This preliminary experiment did not 
use sufficient animal numbers to perform a statistical analysis of the data but did 
demonstrate the ability to detect MPIO-labeled cells arrested in the mouse brain. In 
experiment 2 MPI was performed in vivo and fewer cells were injected to learn more about 
MPI cellular detection sensitivity.  
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Figure 3.2: In vivo MRI of brains in mice injected with 5.0 x 105 (A) or  2.5 x 105 (B) 231BR MPIO labeled cells. 
White arrows point to discrete signal voids generated by MPIO labeled cells arrested in the brain vasculature. The 
white ‘R’ stands for reference tube. Ex vivo MPI of brains from the same mice injected with 5.0 x 105 cells in (C) and 
(E) or 2.5 x 105 cells in (D) and (F). 
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Table 3.1: Summary of data for each mouse in experiment 1. MRI on the day of the cell injection (Day 0) used to verify 
cell injections was quantified for one mouse from each group by measuring the percentage of black pixels above a defined 
threshold.  Quantification of MPI signal and iron content in the brain. 
 
 
In experiment 2, mice were injected with either 2.5 × 105 (n=3) or 5 × 104 (n=3) 
MPIO-labeled 231BR cells and were imaged in vivo with MPI. MPI signal was detected 
in all mouse brains shown in Figure 3.3 where full body MPI scans of mice injected with 
2.5 × 105 or 5 × 104 MPIO-labeled cells can be seen. The average MPI signal and iron 
content measured in the brains of mice that were injected with 2.5 × 105 cells (1.25, 1.65, 
and 1.31 μg Fe; mean = 1.4 μg) was approximately four times greater than in brains injected 
with 5 × 104 cells (0.62, 0.25, and 0.22 μg Fe; mean =  0.37 μg).  
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Figure 3.3: (A) Optical image of mouse in sample bed. (B) In vivo MPI of full body mouse scans injected with 2.5 x 105 
MPIO labeled MDA-231-BR cells and 5.0 x 104 cells (C). 
 
 
 In experiment 3 mice were injected with 5 × 104 MPIO-labeled 4T1BR5 cells (n=4) 
or 5 × 104 Vivotrax-labeled 4T1BR5 cells (n=4) and imaged in vivo with MRI and MPI.  
Day 0 MRI showed distinct signal voids in mouse brains injected with MPIO labeled cells, 
consistent with previous experiments. Vivotrax labeled cells appeared as very faint signal 
voids in MRI which were more difficult to detect and not distinct enough to permit 
quantification. No MPI signal was detected in the brains of mice injected with 
5 × 104 Vivotrax-labeled 4T1BR5 cells (Figure 3.4). MPI signal was detected in all mice 
injected with 5 × 104 MPIO-labeled cells.  
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Figure 3.4: (A) Representative in vivo MRI of a brain from a mouse injected with 5.0 x 104 MPIO labeled 4T1BR5 
cells and the corresponding 3D high resolution in vivo MPI (B). (C) Representative in vivo MRI of a brain from a 
mouse injected with 5.0 x 104 Vivotrax labeled 4T1BR5 cells. White arrows on MR images point to signal voids 
caused by iron-labeled cells. Very few voids were visible in mice injected with Vivotrax labeled cells. 
 
Figure 3.5 A shows the full body MPI scans of mice injected with 5 × 104 MPIO-
labeled cells. The signal can be visualized in all 4 mouse brains. Figure 3.5 B shows a 
representative full body MPI scan of a mouse injected with 5 × 104 Vivotrax labeled cells. 
There is no quantifiable signal seen in this image.  The iron content measured from MPI of 
the brains of mice which were injected with 5 × 104 MPIO-labeled 4T1BR5 cells was 0.21, 
0.33, 0.36 and 0.22 μg Fe, which was not significantly different from that from the 
experiment 2 mice which were injected with the same number of MPIO-labeled 231BR 
cells; average brain iron content was 0.28 μg for 4T1BR5 cells and 0.37 μg for 231BR 
cells.  
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Figure 3.5: (A) Full body MPI scans of mice receiving 5.0 x 104 MPIO labeled 4T1BR5 cell injections. Optical image 
indicates brain location and liver/gut signal. In the bottom right of images is a reference tube. (B) Full body MPI scans 
of mice receiving 5.0 x 104 Vivotrax labeled 4T1BR5 cells where brain signal was not able to be detected.  
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Figure 3.6 illustrates how adjusting the signal intensity in the images and changing 
the FOV affects visibility of the brain signal. Figure 3.6A shows the same 3D whole mouse 
image as shown in Figure 3.5 (first panel) . In B the same image is shown after the signal 
intensity has been adjusted  to show the maximum signal intensity in the brain region. This 
is what is typically done when quantifying the MPI signal; this enhances the ability to see 
regions of low MPI signal but also increases background signal.  
In Figure 3.6 C we tested whether we could use a smaller FOV centered on the 
brain to improve signal detection. Here the FOV was reduced from 12 x 6 x 6 cm  to 4 x 6 
x 6 cm.  At the time, the investigators at Magnetic Insight had not tested this and were 
unsure if this approach would work. As shown, this image has a large region of zero signal 
in the FOV and was not quantifiable. We later learned that the reconstruction algorithm 
makes the assumption that the voxels along the outside edges of the FOV have no iron in 
them and sets the signal to zero and this leads to image distortion and artifact. Although 
iron is not expected to be along the edges of the FOV in this example it is possible that 
MPIO labeled cells are located in the heart, lungs or liver and that this signal extends to the 
edge of the FOV. This issue is still not well studied. In D we further reduced the size of the 
FOV to 3 x 6 x 6 cm and the same artifact did not appear.  The MPI signal in this image 
appears smoother (compared to Figure 3.5).  This may be, in part, because we used the 
high sensitivity scan mode which trades some resolution for sensitivity. The iron content 
measured for this mouse brain was 0.57 μg, compared to 0.33 μg measured from the whole 
body image of the same mouse. This issue requires more study. 
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Figure 3.6: (A) is the same whole body 3D image of the same mouse as in Fig 3.5, first panel. This is showing the image 
displayed without adjusting the signal intensity. (B) The same image has been window/leveled to enhance the signal in 
the mouse brain for quantification. In (C) a smaller FOV 4 x 6 x 6 cm was used, and the scan mode was changed to high 
sensitivity to test whether this improved visualization of brain signal. This image contains artifact attributed to non-zero 
signal at edges of the FOV. (D) The FOV was further reduced to 3 x 6 x 6 cm. This image does not contain the same 
artifact. Oval indicates brain region. 
 
3.4 Discussion 
 This is the first study to demonstrate that MPIO-labeled cells can be detected and 
quantified in vivo by MPI. MPI spatial resolution and sensitivity are heavily influenced by 
the physical properties of the nanoparticle, such as the effective core size, relaxation time 
and size distribution. One way to improve resolution is to increase the (effective) magnetic 
core size of the particles. Tay et al. have found that improved resolution with increasing 
magnetic core size follows the predictions up to approximately 25 nm when the effects of 
SPIO rotational times become significant.23 Sensitivity depends, among other factors, on 
the strength of the nanoparticle magnetization. The magnetization can be increased by 
Small FOV (4cm) Small FOV (3cm) 
3D High Sensitivity 
Original Window Leveled 
3D Isotropic 
A B C D 
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enlarging the iron core diameter, as the strength of the MPI signal increases by the third 
power of the iron core diameter.32 
In the early days of MPI, commercially available SPIOs used for MRI were 
evaluated and Resovist (which is the same as Vivotrax) showed a good MPI performance. 
Although widely used, Vivotrax is now not considered optimal for MPI because it has a 
bimodal size distribution, predominantly containing small cores ~ 5 nm in diameter with a 
small fraction (30%) of multi-core aggregates with an effective size of 24 nm.33  The 
individual cores are too small to magnetize significantly and so the MPI signal only comes 
from the clustered multi-core structures. One approach being taken to improve MPI 
sensitivity is to design similar particles but with a bigger fraction of the aggregates. 
Eberbeck et al. have designed Nanomag-MIP particles which are similar to Vivotrax, they 
are composed of individual cores between 3-8 nm along with multi-core aggregates with 
an effective core size of 19 nm.34 However, for Nanomag-MIP 80% of the nanoparticles 
are of the larger size and the MPI signal is two times larger than that of Resovist. Yoshida 
et al. showed that fractionation of Resovist can improve the MPI signal by 2.5 times.35 
Another approach is the synthesis of homogeneously distributed single-core SPIOs with a 
dedicated iron core diameter for ideal MPI characteristics. Ferguson et al. observed 
increasing MPI signal with increasing magnetic core size (14-27 nm) for monodisperse 
single core particles and up to three times greater signal intensity per unit iron compared 
to multi-core Vivotrax.33  
MPIO are quite different from the nanoparticles typically used for MRI and MPI. 
MPIO consist of multiple small cores (~5-10 nm)36 embedded in polystyrene matrix; 
because of the clustered nature of the iron cores they can be regarded as having one very 
large superparamagnetic core. The 0.9 μm sized MPIO we have used have a broad size 
distribution, the specified range is 0.5-2 μm, however all of these particles would be 
expected to contribute to the MPI signal. MPIO also contain much more iron per particle 
than SPIO.3 
Figure 3.1 shows that the MPI signal generated by the MPIO has reduced resolution 
compared to Vivotrax, consistent with theory. The low resolution is apparent in MPI 
images of MPIO-labeled cells in the mouse brain which show one large area of signal. 
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Unlike, with MRI, it is not possible to determine where within the brain the cells are located 
from the MPI images. Figure 1 shows that the MPI signal for MPIO is greater than that for 
Vivotrax for equal iron concentrations. This suggests that the net change in magnetization 
of the MPIO is greater than the net magnetization change of the same mass of Vivotrax, 
since the MPI signal results from the change in magnetization of an excited particle. The 
high MPI signal produced by MPIO and the high intracellular iron content with MPIO 
labeling both contribute to our increased ability to detect MPIO-labelled cells distributed 
throughout the mouse brain. 
We were able to detect and measure MPI signal in the brains of mice injected with 
as few as 5.0 x 104 MPIO-labeled cells; an intra-cardiac injection of 5 × 104 cells is 
estimated to deliver 10,000 cells to the mouse brain. We did not detect MPI signal in the 
brain when 5.0 x 104 Vivotrax-labeled cells were injected. This is, in part, due to the fact 
that cell labeling with MPIO is more efficient than for Vivotrax (~90% versus 70% of cells 
labeled) and the amount of iron per cell is significantly greater for MPIO than Vivotrax 
labeling (20-30 pg/cell versus 10-15 pg/cell). Our MRI data for Vivotrax cells in the brain 
supports this; signal voids were considerable fainter and harder to detect in MR images of 
mouse brains which received Vivotrax-labeled cells. Furthermore, the MPI signal 
generated from MPIO is higher than Vivotrax. While Vivotrax is currently the most 
common SPIO used for MPI, our results show that MPIO-labeled cells can be detected and 
quantified in this mouse brain model more readily than Vivotrax-labeled cells. It is worth 
noting that MPIO are inert, nonbiodegradable particles only suitable for preclinical 
experimental studies.  
MPI provided information which was not attainable with MRI. With knowledge of 
the amount of iron per cell achieved with labeling the cell number could be estimated.  Our 
routine measurements of mean iron/cell after labeling the cancer cell lines used in this study 
with MPIO are consistently in the range of 20-30 pg of iron/cell, using inductively-coupled 
mass spectrometry (ICP-MS). As described above, with an estimate of 20% of injected 
cells arresting in the brain the intra-cardiac injections of 5.0 x 105, 2.5 x 105 and 5 x 104 
cells will deliver approximately 100,000, 50,000 and 10,000 cells to the brain, respectively. 
Using the higher value (30 pg) for MPIO labeling of cells, for example, this amounts to 
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approximately 3.0, 1.5 and 0.3 μg of iron in the brain due to iron-labeled cell burden. As 
shown in Table 3.2, our data falls within these approximations.   
There are a number of factors which make it impossible to calculate true cell number in 
our study.  First, the value for iron/cell that we measure from ICP-MS or MPI is an average 
value, some cells will contain more iron, some less. Second, the amount of iron/cell 
achieved with each cell labeling experiment has a range of values, even for the same 
labeling protocol, depending on precise timing and culture conditions. Third, the number 
of cells delivered to the brain by intra-cardiac injection is an estimation. We used an 
estimate of 20% of cardiac output to the brain resulting in 20% of cells delivered; published 
values are between 5-25%.37 Intra-cardiac injections are also technically challenging and, 
while we have significant expertise, not every injection is likely to deliver the exact same 
number of cells. Lastly, there may be an upper limit to the number of cells that arrest and 
then persist in the brain. For these last two reasons, there are unlikely to be double the 
number of cells arrested in the brain with double the number injected. These factors are 
also likely the reason why different values for iron content in the brain were measured for 
mice injected with the same number of MPIO-labeled cells, but in different experimental 
groups (i.e., mice that received 2.5 x 105 MPIO-labeled cells in experiment 1 and 2).  
Considering all these caveats our values for iron content measured by MPI are in good 
agreement with the rough estimate of iron expected in the brain. In conclusion, we have 
demonstrated that MPIO-labeled cells can be detected and quantified in vivo in a model 
where cells are dispersed throughout the mouse brain. 
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Table 3.2: Summary of all experiments, showing the number of cells injected intra-cardiac, the estimated number of cells 
arrested in the brain, the estimated amount of iron per cell, the estimated amount of iron in the brain and the measured 
iron content in the b rain and the measured iron content in the brain from MPI images. 
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Chapter 4  
4 Conclusions, Limitations, and Future Work  
This Chapter summarizes all the findings in the experiments in this thesis. 
Limitations and future work. 
 
4.1 Discussion and Conclusions 
4.1.1 Chapter 2 Summary and Discussion 
Relaxometry data was collected for MPIO and Vivotrax to compare the sensitivity 
and resolution of each particle. The amplitude of the MPI signal for MPIO was higher than 
Vivotrax; the relative sensitivity was 1.5 for MPIO versus Vivotrax. However, Vivotrax 
outperformed MPIO in resolution.  The calculated resolution for MPIO was 4.49 mm 
versus 1.69 mm for Vivotrax. For our application where the goal was to estimate the 
number of cancer cells in the mouse brain sensitivity was most important and therefore 
MPIO was used for subsequent mouse studies. 
The generation of calibration lines was a method we developed to quantify the iron 
content in MPI images acquired in this chapter and in chapter 3. Calibration lines were 
made for MPIO and Vivotrax for each scan mode used to image samples or mice. A series 
of samples of each SPIO were diluted in PBS into aliquots to be scanned. These samples 
were then measured using area/volume multiplied by mean signal to give us our total MPI 
signal value. Total MPI signal was then plotted against the known iron content of each 
dilution sample. Total MPI signal and iron content are linearly related so we use the slope 
of that line to help us calculate the amount of iron content in our experiments. Calibration 
lines provide a more accurate means of quantification compared to using reference tubes. 
This is because reference tubes are images with the experimental sample and therefore the 
iron content in these reference tubes needs to have similar iron content to what is in the 
experimental sample. Sometimes this is not always known, especially in vivo. If the 
amount of iron in the reference tube is too much it can overwhelm the signal you are 
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actually trying to detect. If it is too low, it can be overwhelmed by the signal you are trying 
to detect and then total MPI signal cannot be calculated from your reference tube.  
Repeatability of the MPI measurements was assessed to determine the amount of 
variability there was when acquiring MPI images and quantifying data. In experiment 1, 
samples were scanned six times without being removed from their position on the MPI 
bed. Those same samples were then taken out and placed back in the MPI bed, in between 
individual scans, for another round of six scans. Lastly, the samples were placed at the 4 
cm mark on the MPI and scanned six times without being moved. The reason for moving 
samples to different locations was based on our observations of changes in the location of 
background signal due to noise. These results showed that there is some variation in the 
measurements for all experiments. The ‘true’ iron content for the Vivotrax sample 
(determined using manufacturer’s stated iron concentration) was 27.5 μg and the mean 
values measured for the three conditions were 28.5, 28.9 and 29.0, which are within 6% of 
the value given by the manufacturer Magnetic Insight Inc. For the MPIO sample, the iron 
content was 14 μg and the mean values for the three conditions were 17.4, 19.5 and 20.3, 
which are farther off. This is most likely due to the fact that since MPIO particles are so 
large they have a tendency to quickly  to settle at the bottom of the tube when samples were 
loaded in. This essentially creates an even larger particle as all the MPIO particles interact 
when they are in close proximity to each other. This can affect how the particle reacts in 
the MPI system as larger particles experience more Brownian relaxation creating a slower 
loss in magnetization which negatively affects the resolution quality. This most likely lead 
to a larger volume being calculated when measuring the MPIO sample ROIs in the MPI 
scans which is used to calculated iron content. 
Reproducibility was tested by having the same sample scanned and quantified by 3 
different MPI users. Our results showed that even though these users were analyzing the 
same sample using the same quantification methods and calibration line there was some 
variability in iron mass calculated. User 1 and 2 results were not significantly different 
from one another. However, the results for user 3 were significantly different from user 1 
and 2. This is likely because of the subjectivity involved with manually drawing ROIs 
around the MPI signal. In this case we determined that user 3 was drawing larger ROIs 
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than user 1 and 2. This larger volume influences the calculation of  total MPI signal which 
is subsequently used to calculate iron content.  
The detection of cell samples was explored using a range of cell numbers, from 2.5 
x 103  to  2.5 x 105 cells, labeled with either MPIO or Vivotrax. Images were acquired with 
the 2D high sensitivity isotopic scan mode and no signal averaging. For both MPIO and 
Vivotrax, samples that contained less than 1.0 x 104 cells showed high background signal 
(lower SNR) and were not clearly visualized. In these images the MPI signal was difficult 
to quantify since the signal of interest could not be discriminated from the background 
noise. For the lower 2.5 x 103 cell samples, increased averaging (8) allowed for detection 
and quantification of the MPI signal, although with the trade-off of increased scan time. 
Using a 3D scan could have also been a way to improve the amount of signal visualized in 
MPI images.  
4.1.2 Chapter 3 Summary and Discussion 
In Chapter 3 we studied whether MPIO could be used for labeling cells to be 
detected by MPI. Our prior work using MRI to track MPIO-labeled cancer cells in the brain 
showed very high sensitivity, down to single cell under ideal conditions, and allowed us to 
monitor both proliferative and non-proliferative cell populations.  However, we could not 
determine cell number from our MRI data. We were able to detect and quantify the MPI 
signal in mice which received intra-cardiac injections of different numbers of cells, 
amounting to detection limits of approximately 25,000, 50,000 or 100,000 cells in the 
mouse brain. These are estimates based on what is known about how many cells are 
expected to arrest in the brain vasculature after intra-cardiac injection. To calculate the 
exact cell number was not possible considering this estimate and factor related to MPIO 
cell labeling. We used an estimate of 20 pg of iron per cell based on prior measurements 
made in the Foster lab using the same MPIO and the same cell type. However, the iron 
loading does vary from experiment to experiment, even in the same lab under the same 
conditions, and this number is an average value, some cells contain more and less iron. 
Still, our values for iron content measured from in vivo mouse MPI were 0.2 to 0.7 
μg for mice injected with 50,000 cells where the estimated iron content in the brain was 
0.3 μg; 1.3 to 3.2 μg for mice injected with 250,000 cells where the estimated iron content 
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in the brain was 1.5 μg; and 3.0 – 3.3 μg for mice injected with 500,000 cells where the 
estimated iron content in the brain was 3.0 μg. MPI provided quantitative information 
which could not be extracted from MRI data.   
There are currently two other papers that have used MPIO labeled cells for MPI. 
Mallett et al. fed mice 3 different types of diet that contained varying amounts of iron to 
mimic livers with different endogenous iron loadings. MPIO-labeled cancer cells were later 
delivered to the liver via intrasplenic injection. The mice were then imaged in vivo using 
MRI. In images with high iron loading the MPIO-labeled cells could not be detected. This 
is because all types of iron generate signal loss in MR images. Livers were harvested and 
imaged ex vivo by MPI afterward and MPIO-labeled cells could be detected in all livers, 
demonstrating a role for MPI cell tracking in models of excessive liver iron or iron 
overload.1 In a preprint by Parkins et al. (where I am a co-author and acquired and analyzed 
the MPI data) a primary tumour was generated by injecting unlabeled 231-BR cancer cells 
into the mouse mammary fat pad. After 41 days of growth MPIO-labeled MDA-MB-
231BR-eGFP cells were injected intracardially into the left ventricle of the mouse heart. 
Mice were imaged using MPI 3 days after this injection and the images showed that MPIO-
labeled cells could be detected in the established MDA-MB-231 primary tumour.2 The 
work in this thesis is novel in that it is the first show that MPIO-labeled cancer cells 
dispersed in the mouse brain can be detected and quantified using in vivo MPI.  
 
4.2 Challenges and Limitations 
4.2.1 Late Arrival of MPI 
I began my graduate work in January 2019. The MomentumTM MPI system was 
originally supposed to be installed in April 2019.  Unfortunately, the system was 
damaged during delivery from Alameda, California, USA to London, ON, Canada and 
had to be shipped back. A new system was installed in August 2019. This resulted in a 
delay of 4 months on planned experiments. Once the system was installed, we wasted no 
time in making sure the system was calibrated and ready for use. 
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4.2.2 Contamination 
Contamination of the MPI system occurs easily due to iron that can be in multiple different 
products that are common in a lab. For example, dust, paper towels, certain tapes, scissor 
cuts can all introduce residual iron which if present in the bore of the system or on the 
sample beds, can produce unwanted signal which the manufacturer refers to as 
contamination. When there is contamination the background signal is higher than normal. 
We now routinely collect an empty bed scan before starting experiments. Figure 4.1 shows 
an example of an empty bed scan where the background is clear from contamination and a 
bed that is considered contaminated.  
Contamination will always be an issue; however, it can be minimized. We have 
installed a plastic shield to cover the entrance to the bore of the MPI system. This shield 
stays on at all times, except when scans are in progress. Second, we make sure that the MPI 
sample bed is wiped and sanitized with 70% ethanol before and after each scan. We also 
run empty bore and empty bed scans before imaging samples to ensure there is no serious 
contamination in the bore. We also keep the MPI room clean by continuously wiping down 
surfaces and floors to minimize dust build up. Recently, we had a more serious 
contamination inside the bore of the MPI system and have now installed a compressed air 
hose in the MPI lab to regularly blow out any source of contamination that may settle inside 
the bore. 
 
 
Figure 4.1: (A) Mouse feed in 50ml falcon tube. (B) 2D high sensitivity MPI scan of mouse feed overlaid on top of 
optical image of mouse feed. 
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4.2.3 Unwanted Sources of Signal 
There is also an issue with detecting sources of unwanted signal. Sometimes MPI 
signal is  detected in the gut of mice due to the presence of iron in mouse feed. Figure 4.2 
shows a 50 ml tube full of the mouse chow scanned by MPI which produced signal. This 
signal is typically low intensity but can become a problem when trying to quantify signal 
that is of similar iron concentration such as a low cell number or when using an SPIO with 
lower iron content. It becomes especially difficult when the signal of interest is in close 
proximity to the unwanted mouse gut signal. MPI of a control, uninjected mouse is shown 
in Figure 4.3. A strong signal is observed in the region of the abdomen, likely due to mouse 
feed. We have also observed MPI signal at the site of injection of cells, from dried blood 
in the form of hemosiderin from needle pricks (not shown).  
 
 
Figure 4.2: Naïve mouse scanned using a 2D high sensitivity MPI scan where signal can be seen coming from the gut 
from mouse feed. 
 
 
Figure 4.3: (A) Uncontaminated MPI bed. (B) Contaminated MPI bed. 
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4.2.4 COVID-19 Pandemic 
As we all know COVID-19 has created challenges for everyone. During the 
pandemic when our labs at Robarts were shut down from mid-March until June, I was 
unable to conduct any experiments to complete work for this thesis. The in vivo work in 
Chapter 3 was most affected by this shutdown. However, despite the world shutting down 
for most of 2020 I was able to complete as many experiments as I could and write this 
thesis in time for submission. 
4.2.5 Limitations of MPI 
MPI itself has several limitations, some which are common to other imaging 
modalities and some that are unique to MPI, and others that we are just learning about as 
our lab works on developing and advancing this emerging imaging modality.  
The resolution of MPI is considered low in relation to MRI, and similar to micro-
PET. Resolution is considered the main limitation of MPI but it is also a feature of MPI 
that is expected to improve dramatically over time as advances in MPIO tailored 
nanoparticles are made.  Also, similar to PET imaging, MPI images provide no anatomical 
information. Anatomical information has to be obtained through additional separate scans 
from either CT or MRI and then co-registered to learn exactly where a signal is originating 
from. Magnetic Insight Inc. recently made available a dual modality MPI/CT system that 
allows the CT image to be obtained without moving the subject. The MPI system at Robarts 
is equipped with a camera that takes a photo of the subject in the FOV and this provide a 
rough anatomical reference for users when overlayed with an MPI image. Like MRI, MPI 
is unable to differentiate between live or dead iron labeled cells. When iron labeled cells 
die, they may release the iron label which can be taken up by phagocytic cells such as 
macrophages. This issue is known as bystander cell uptake and can lead to 
misinterpretation of the signal as the cells of interest. 
It is not possible to use a small, focused region of interest in MPI.  For MRI, we are 
used to choosing a FOV that fits around our region of interest and determines the voxel 
size and influences the scan time. In MPI, the reconstruction algorithm makes the 
assumption that the voxels along the outside edges of the FOV have no iron in them and 
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sets the signal to zero.  When the edge of the FOV goes through the mouse (as in Chapter 
3, Figure 3.6 C)  there will be image distortion and negative signal, this can be major or 
minor and depending on the quantity and volume of iron at the edge of the FOV but results 
in data that is not quantifiable. This is an example of an issue that was unfamiliar to even 
the scientists at Magnetic Insight Inc. and one of the many challenges associated with 
implementing a new imaging modality for cell tracking. In our lab we regard these as 
welcomed challenges and are excited about doing what we can to advance this technology. 
4.2.6 Limitations of Study 
Limitations of the experiments in this thesis are listed here: 
1. During the experiments in 2.3.4 MPIO Labeled Cell Viability After MPI, the cell 
samples were scanned using the 2D high sensitivity scan mode which takes ~ 2 
minutes and uses a weak gradient (3 T/m). This may not affect cell viability as much 
as a longer scan or a stronger gradient would.  
2. Labeling cells with Vivotrax leads to some extracellular iron and some iron on the 
cell surface. We didn’t fully understand the extent of this at the time our 
experiments were conducted. This excess iron will lead to more MPI signal and an 
overestimation of the iron content measured from the images. 
3. The number of animals used in all of the in vivo experiments in Chapter 3 should 
be increased. 
4. At the time of these studies, we did not have access to ICP-MS which we now use 
to measure iron mass per cell (used in conversion of iron content measured by MPI 
to cell number). Therefore, the estimates of cell number from in vivo MPI images 
of the mouse brains in Chapter 3, experiments 2 and 3 used values which were 
measured in the past in the Foster lab for MPIO and the same cell type.  
Future work, which could address these limitations is described below. 
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4.3 Future Work  
4.3.1 Next Steps 
Next steps for this project would be to add additional mice to all the in vivo 
experiments conducted in Chapter 3.  Mouse group sizes for experiments 2 and 3 were 
determined using an a priori power calculation using expected effect sizes based on 
previous studies that used MRI to detect differences in the number of signal voids for mice 
injected with different numbers of cells.  A study with an effect size of 1.08 and power of 
80% required 8 mice/group to test the association at 5% using two-tailed test.  
Since we were able to detect MPI signal with as few as 5 x 104 MPIO-labeled cells 
injected intra-cardiac (~10,000 cells estimated in brain) it would be interesting to reduce 
the number of cells injected until we are unable to detect MPI signal. One paper estimates 
that MPI should be able to detect 200 Vivotrax labeled cells.3 This estimate was based on 
the SNR of an ex vivo cell sample. A study which used a SPIO designed and synthesized 
specifically for MPI has demonstrated the detection of 250 cells injected in a bolus 
intramuscularly a mouse.4   
Access to an advanced user interface was granted to the Foster lab by Magnetic 
Insight Inc. in summer 2020.  This allows users to adjust more imaging parameters and 
optimize MPI acquisitions. Having this ability could increase imaging sensitivity allowing 
for lower cell numbers to be detected in vivo. The in vivo work done in Chapter 3 at the 
start of using MPI was all scanned used basic imaging parameters. Due to COVID-19, I 
did not have the time to repeat these experiments to test options in the advanced interface.   
Ultimately, we are interested in tracking MPIO-labeled cells over time in the mouse 
brain as cells proliferate and detecting and quantifying the number of cells that persist as 
non-proliferative MPIO-retaining cells. This work is beyond the scope of my thesis. My 
results show that it is possible to detect and quantify MPIO-labeled cells in this model and 
these techniques, possibly along with advanced imaging parameters, may allow for this 
additional work by a new student.   
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As described above, the original experiment to test whether MPI affected cell 
viability was done using a 2D high sensitivity scan which is not only a short scan but also 
a scan that uses the weakest gradient strength (3 T/m). The viability test should be repeated 
using an MPI scan that is longer and uses a stronger gradient (i.e., 3D isotropic scan). This 
may provide more realistic information on cell viability especially as in vivo work will 
almost always be done using some sort of 3D scan.  
Unwanted signal from the gut was an issue that was intermittent and bothersome, 
and this has been observed by several other users. In the future we plan to purchase an iron-
free mouse chow which we can switch mice over to a week prior to imaging. We hope this 
will eliminate this problem. Another solution may be fasting mice 24 hours prior to 
scanning to ensure elimination of food by-products in the gut.  
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Appendices 
 
Appendix A: TEM images of (A) MPIO and (B) Vivotrax. Images provided by the manufacturers. 
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